<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2708234054
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        TRACLEER 125 MG FILM COATED TABLET
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        BOSENTAN
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        125
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        56
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        do not store above 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        7526.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Haupt Pharma Wulfing GmbH" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Haupt Pharma Wulfing GmbH
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            ACTELTION PHARMACEUTICALS LTD
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C02KX01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Tracleer tablets contain bosentan, which blocks a naturally occurring hormone called endothelin-1 (ET-1), which causes blood vessels to narrow. Tracleer therefore causes blood vessels to expand and belongs to the class of medicines called &ldquo;endothelin receptor antagonists&rdquo;.</p><p>&nbsp;</p><p>Tracleer is used to treat:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Pulmonary arterial hypertension</strong> (PAH): PAH is a disease of severe narrowing of the blood vessels in the lungs resulting in high blood pressure in the blood vessels (the pulmonary arteries) that carry blood from the heart to the lungs. This pressure reduces the amount of oxygen that can get into the blood in the lungs, making physical activity more difficult. Tracleer widens the pulmonary arteries, making it easier for the heart to pump blood through them. This lowers the blood pressure and relieves the symptoms.</p><p>&nbsp;</p><p>Tracleer is used to treat patients with class III PAH to improve exercise capacity (the ability to carry out physical activity) and symptoms. The &lsquo;class&rsquo; reflects the seriousness of the disease: &lsquo;class III&rsquo; involves marked limitation of physical activity. Some improvements have also been shown in patients with class II PAH. &lsquo;Class II&rsquo; involves slight limitation of physical activity. The PAH for which Tracleer is indicated can be:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; primary (with no identified cause or familial);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; caused by scleroderma (also called systemic sclerosis, a disease where there is abnormal growth of the connective tissue that supports the skin and other organs);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; caused by congenital (inborn) heart defects with shunts (abnormal passageways) causing abnormal flow of blood through the heart and lungs.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Digital ulcers</strong>: (sores on the fingers and toes) in adult patients with a condition called scleroderma. Tracleer reduces the number of new finger and toe ulcers that appear.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Tracleer:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are allergic</strong> <strong>to bosentan</strong> or any of the other ingredients of this medicine (listed in section&nbsp;6)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you have</strong> <strong>liver problems</strong> (ask your doctor)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are pregnant, or could get pregnant </strong>because you are not using reliable contraceptive methods. Please read the information under &ldquo;Contraceptives&rdquo; and &ldquo;Other medicines and Tracleer&rdquo;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>if you are taking cyclosporine A</strong> (a medicine used after a transplant or to treat psoriasis)</p><p>&nbsp;</p><p>If any of these apply to you, tell your doctor.</p><p>&nbsp;</p><p><strong>Warnings and precautions</strong></p><p><strong>Tests your doctor will do before treatment</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a blood test to check your liver function</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a blood test to check for anaemia (low haemoglobin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; a pregnancy test if you are a woman of childbearing potential</p><p>Some patients taking Tracleer have been found to have abnormal liver function tests and anaemia (low haemoglobin).</p><p>&nbsp;</p><p><strong>Tests your doctor will do during treatment</strong></p><p>During treatment with Tracleer, your doctor will arrange for regular blood tests to check for changes in your liver function and haemoglobin level.</p><p>&nbsp;</p><p>For all these tests please refer also to the Patient Alert Card (inside your pack of Tracleer tablets). It is important that you have these regular blood tests as long as you are taking Tracleer. We suggest you write the date of your most recent test and also of your next test (ask your doctor for the date) on the Patient Alert Card, to help you remember when your next test is due.</p><p>&nbsp;</p><p><strong><u>Blood tests for liver function</u></strong></p><p>These will be done every month for the duration of treatment with Tracleer. After an increase in dose an additional test will be done after 2&nbsp;weeks.</p><p>&nbsp;</p><p>Blood tests for anaemia</p><p>These will be done every month for the first 4 months of treatment, then every 3 months after that, as patients taking Tracleer may get anaemia.</p><p>&nbsp;</p><p>If these results are abnormal, your doctor may decide to reduce your dose or stop treatment with Tracleer and to perform further tests to investigate the cause.</p><p><u>&nbsp;</u></p><p>Children and adolescents</p><p>Tracleer is not recommended in paediatric patients with systemic sclerosis and ongoing digital ulcer disease. Please see also section 3. How to take Tracleer.</p><p>&nbsp;</p><p><strong>Other medicines and Tracleer</strong></p><p>Please tell your doctor or pharmacist if you are taking or have recently taken any other medicines, including medicines obtained without a prescription. It is especially important to tell your doctor if you are taking:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporine A (a medicine used after transplants and to treat psoriasis), which must not be used together with Tracleer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; sirolimus or tacrolimus, which are medicines used after transplants, as these are not recommended to be used together with Tracleer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; glibenclamide (a diabetes medicine), rifampicin (a tuberculosis medicine), fluconazole (a medicine against fungal infections), ketoconazole (a medicine used to treat Cushing&rsquo;s syndrome), or nevirapine (an HIV medicine), as these medicines are not recommended to be used together with Tracleer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines for the treatment of HIV infection, which may require special monitoring if used together with Tracleer.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hormonal contraceptives, which are not effective as the sole method of contraception when you take Tracleer. Inside your pack of Tracleer tablets you will find a Patient Alert Card which you should read carefully. Your doctor and/or gynaecologist will establish the contraception which is appropriate for you.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medications for the treatment of pulmonary hypertension: sildenafil and tadalafil;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin (an anticoagulant agent);</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; simvastatin (used to treat hypercholesterolaemia).</p><p>&nbsp;</p><p><strong>Driving and using machines</strong></p><p>Tracleer has no or negligible influence on the ability to drive and use machines. However, Tracleer can induce hypotension (decrease of your blood pressure) which can make you feel dizzy, affect your vision and affect your ability to drive and use machines. Therefore, if you feel dizzy or that your vision is blurred while taking Tracleer, do not drive or operate any tools or machines.</p><p>&nbsp;</p><p><strong>Women of childbearing age</strong></p><p>Do NOT take Tracleer if you are pregnant or planning to become pregnant.</p><p>&nbsp;</p><p><strong>Pregnancy tests</strong></p><p>Tracleer may harm unborn babies conceived before starting or during treatment. If you are a woman who could become pregnant, your doctor will ask you to take a pregnancy test before you start taking Tracleer, and regularly while you are taking Tracleer.</p><p><em><u>&nbsp;</u></em></p><p><strong>Contraceptives</strong></p><p>If it is possible that you could become pregnant, use a reliable form of birth control (contraception) while you are taking Tracleer. Your doctor or gynaecologist<em> </em>will advise you about reliable contraceptive methods while taking Tracleer. Because Tracleer may make hormonal contraception (e.g., oral, injection, implant, or skin patches) ineffective, this method on its own is not reliable. Therefore, if you use hormonal contraceptives you must also use a barrier method (e.g., female condom, diaphragm, contraceptive sponge, or your partner must also use a condom). Inside your pack of Tracleer tablets you will find a Patient Alert Card. You should complete this card and take it to your doctor at your next visit so that your doctor or gynaecologist can assess whether you need additional or alternative reliable contraceptive methods. Monthly pregnancy tests are recommended while you are taking Tracleer and are of childbearing age.</p><p>&nbsp;</p><p>Tell your doctor immediately if you become pregnant while you are taking Tracleer, or plan to become pregnant in the near future.</p><p><em><u>&nbsp;</u></em></p><p><strong>Breast-feeding</strong></p><p><strong>Tell your doctor</strong> immediately <strong>if you are breast-feeding</strong>. You are advised to stop breast-feeding if Tracleer is prescribed for you, because it is not known whether this medicine passes into breast milk.</p><p>&nbsp;</p><p><strong><u>Fertility</u></strong></p><p>If you are a man taking Tracleer, it is possible that this medicine may lower your sperm count. It cannot be excluded that this may affect your ability to father a child. Talk to your doctor if you have any questions or concerns about this.</p><p>&nbsp;</p><p><strong>Tracleer contains sodium</strong></p><p>This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Treatment with Tracleer should only be started and monitored by a doctor who has experience in the treatment of PAH or systemic sclerosis. Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p><strong>Tracleer with food and drink</strong></p><p>Tracleer can be taken with or without food.</p><p>&nbsp;</p><p><strong>Recommended dose</strong></p><p>&nbsp;</p><p><strong>Adult</strong></p><p>The treatment in adults is usually started for the first 4&nbsp;weeks with 62.5&nbsp;mg twice daily (morning and evening), from then your doctor will usually advise you to take a 125&nbsp;mg tablet twice daily, depending on how you react to Tracleer.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>The dose recommendation in children is only for PAH.<strong><em> </em></strong>For children aged 1 year and older, treatment with Tracleer is usually started with 2 mg per kg bodyweight twice daily (morning and evening). Your doctor will advise you on your dosing.</p><p>&nbsp;</p><p>Please note that Tracleer is also available as a dispersible 32 mg tablet formulation, which may make correct dosing easier for children and patients with low body weight or difficulties to swallow film-coated tablets.</p><p>&nbsp;</p><p>If you have the impression that the effect of Tracleer is too strong or too weak, talk to your doctor in order to find out whether your dose needs to be changed.</p><p>&nbsp;</p><p><strong>How to take Tracleer</strong></p><p>Tablets should be taken (morning and evening), swallowed with water. The tablets can be taken with or without food.</p><p>&nbsp;</p><p><strong>If you take more Tracleer</strong> <strong>than you should</strong></p><p>If you take more tablets than you have been told to take, contact your doctor immediately.</p><p>&nbsp;</p><p><strong>If you forget to take Tracleer</strong></p><p>If you forget to take Tracleer, take a dose as soon as you remember, then continue to take your tablets at the usual times. Do not take a double dose to make up for forgotten tablets.</p><p>&nbsp;</p><p><strong>If you stop taking</strong><strong> Tracleer</strong></p><p>Suddenly stopping your treatment with Tracleer may lead to your symptoms getting worse. Do not stop taking Tracleer unless your doctor tells you to. Your doctor may tell you to reduce the dose over a few days before stopping completely.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>The most serious side effects with Tracleer are</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal liver function which may affect more than 1 in 10 people</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaemia (low blood value) which may affect up to 1 in 10 people. Anaemia may occasionally require blood transfusion</p><p>Your liver and blood values will be monitored during treatment with Tracleer (see section 2). It is important that you have these tests as ordered by your doctor.</p><p>&nbsp;</p><p>Signs that your liver may not be working properly include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; nausea (urge to vomit)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; vomiting</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (high temperature)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pain in your stomach (abdomen)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; jaundice (yellowing of your skin or the whites of your eyes)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark-coloured urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itching of your skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lethargy or fatigue (unusual tiredness or exhaustion)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; flu-like syndrome (joint and muscle pain with fever)</p><p>&nbsp;</p><p>If you notice any of these signs <strong>tell your doctor immediately</strong>.</p><p><u>&nbsp;</u></p><p><u>Other side effects: </u></p><p><u>&nbsp;</u></p><p><strong>Very common </strong>(may affect <strong>more than one in 10</strong> people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oedema (swelling of the legs and ankles or other signs of fluid retention)</p><p><u>&nbsp;</u></p><p><strong>Common (</strong>may affect<strong> up to one in 10</strong> people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Flushed appearance or redness of skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hypersensitivity reactions (including skin inflammation, itching and rash)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Gastrooesophageal reflux disease (acid reflux)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Syncope (fainting)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Palpitations (fast or irregular heart beats)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nasal congestion</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect<strong> up to one in 100</strong> people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Thrombocytopenia (low number of blood platelets)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Neutropenia/leukopenia (low number of white blood cells)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated liver function tests with hepatitis (inflammation of the liver) including possible exacerbation of underlying hepatitis and/or jaundice (yellowing of the skin or the whites of the eyes)</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect <strong>up to one in 1000</strong> people):</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anaphylaxis (general allergic reaction), angioedema (swelling, most commonly around the eyes, lips, tongue or throat)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cirrhosis (scarring) of the liver, liver failure (serious disturbance of liver function)</p><p>&nbsp;</p><p>Blurred vision have also been reported at an unknown frequency (frequency cannot be estimated from the available data).</p><p><strong>&nbsp;</strong></p><p><strong>Side effects in children and adolescents</strong></p><p>The side effects that have been reported in children treated with Tracleer are the same as those in adults.</p><p>&nbsp;</p><p><strong>Reporting of side effects</strong></p><p>If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton after &ldquo;EXP&rdquo;.</p><p>For white high-density polyethylene bottles, use within 30 days after the first opening.</p><p>&nbsp;</p><p>Do not store above 30 &deg;C.</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away any medicines you no longer use. These measures will help to protect the environment.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>What Tracleer contains</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tracleer 125 mg film-coated tablets:</strong> The active substance is bosentan as monohydrate. Each tablet contains 125 mg of bosentan (as monohydrate).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>The other ingredients</strong> in the tablet core are maize starch, pregelatinised starch, sodium starch glycolate (Type A), povidone, glycerol dibehenate and magnesium stearate. <strong>The film-coat</strong> contains hypromellose, glycerol triacetate, talc, titanium dioxide (E171), iron oxide yellow (E172), iron oxide red (E172) and ethylcellulose.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Tracleer 125 mg film-coated tablets are orange-white, oval film-coated tablets with “125” on one side.
	
White high-density polyethylene bottles with a silica gel desiccant containing 56 film-coated tablets. Cartons contain 56 film-coated tablets (Tracleer 125 mg film-coated tablets).
Do not swallow the desiccant.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing authorisation holder:</strong></p><p>Actelion Pharmaceuticals Ltd</p><p>Gewerbestrasse 16</p><p>4123 Allschwil</p><p>Switzerland</p><p>&nbsp;</p><p><strong>Manufacturer:</strong></p><p>Haupt Pharma W&uuml;lfing GmbH Bethelner Landstrasse 18 31028 Gronau &ndash; Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                	To contact us , please visit our website  www.janssen.com/contact-us  
	
	This leaflet was last revised in 05 September 2019

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي أقراص تراكلير على بوسينتان، الذي يعيق إفراز الهرمون الطبيعي المسمى الإندوثيلين - 1 (ET-1) الذي يسبب انقباض الأوعية الدموية. لهذا، يتسبب دواء تراكلير في تمدد الأوعية الدموية وينتمي إلى فئة الأدوية المسماة &quot;مضادات مستقبلات الإندوثيلين&quot;.</p><p>&nbsp;</p><p dir="RTL">يُستخدم دواء تراكلير في علاج الأمراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>ارتفاع ضغط الدم الشرياني الرئوي</strong> (PAH): ارتفاع ضغط الدم الشرياني الرئوي مرض يؤدي إلى انقباض شديد في الأوعية الدموية في الرئتين، مما يؤدي إلى ارتفاع ضغط الدم في الأوعية الدموية (الشرايين الرئوية) التي تحمل الدم من القلب إلى الرئتين. يُقلص هذا الضغط مقدار الأكسجين الذي يمكن أن يدخل الدم في الرئتين، وبهذا يشعر المريض بصعوبة شديدة في القيام بأنشطته البدنية. يقوم تراكلير بتمديد الشرايين الرئوية، وبهذا يُسهل على القلب ضخ الدم عبر تلك الشرايين. وبهذا ينخفض ضغط الدم وتخف تلك الأعراض.</p><p>&nbsp;</p><p dir="RTL">يُستخدم دواء تراكلير في علاج المرضى من الفئة الثالثة من ارتفاع الضغط الشرياني الرئوي بهدف تحسين قدارتهم (على أداء أنشطتهم البدنية) وتخفيف الأعراض. وتُشير &quot;الفئة&quot; إلى خطورة المرض: تنطوي &quot;الفئة الثالثة&quot; على القصور الشديد في النشاط البدني. ولقد تحسنت أيضاً حالات بعض المرضى المصابين بهذا المرض من الفئة الثانية. تنطوي &quot;الفئة الثانية&quot; على قصور خفيف في النشاط البدني. قد تكون حالة ارتفاع ضغط الدم الشرياني الرئوي التي يُستخدم دواء تراكلير في علاجها كما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أولية (دون سبب معروف أو لأسباب وراثية)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ناتجة عن مرض التصلب الجلدي (المُسمى أيضاً التصلب المجموعي، حيث تنمو الأنسجة الضامة التي تدعم الجلد والأعضاء الأخرى نمواً غير طبيعي)؛</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ناتجة عن عيوب القلب الخلقية (الطبيعية) المتعلقة بالتحويلة (مسارات غير طبيعية)، والتي تؤدي إلى تدفق الدم بصورة غير طبيعية عبر القلب والرئتين.</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>قُرح الأصابع</strong>: (تقرحات أصابع اليدين والقدمين) في حالات المرضى من كبار السن المصابين بمرض التصلب الجلدي. يقلل دواء تراكلير من عدد القُرح الجديدة التي تصيب أصابع اليدين والقدمين التي قد تظهر.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يحظر تناول دواء تراكلير في الحالات التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني من الحساسية</strong> <strong>من بوسينتان</strong> أو أي من مكونات الدواء الأخرى (المذكورة في القسم 6)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تعاني</strong> <strong>من مشكلات في الكبد</strong> (استشر الطبيب المعالج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنتِ حاملاً أو يمكن أن تحملي </strong>لأنك لا تستخدمين وسيلة موثوقة لمنع الحمل. يُرجى قراءة المعلومات المذكورة في قسم &quot;وسائل منع الحمل&quot; وقسم &quot;الأدوية الأخرى ودواء تراكلير&quot;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>إذا كنت تتناول عقار سيكلوسبورين </strong><strong>A</strong> (عقار يُوصف بعد زراعة عضو أو في علاج الصدفية)</p><p>&nbsp;</p><p dir="RTL">أخبر الطبيب المعالج إذا كانت أي من تلك الحالات تنطبق عليك.</p><p>&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong></p><p dir="RTL"><strong>الاختبارات التي سيجريها الطبيب المعالج قبل بدء العلاج</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار دم للتأكد من حالة وظائف الكبد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار دم للتأكد من عدم الإصابة بالأنيميا (انخفاض مستوى الهيموجلوبين في الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اختبار حمل، إذا كنتِ امرأة قادرة على الإنجاب</p><p dir="RTL">لقد وُجد أن بعض المرضى ممن يتناولون دواء تراكلير كانت اختبارات وظائف الكبد والأنيميا لديهم غير عادية (انخفاض مستوى الهيموجلوبين).</p><p>&nbsp;</p><p dir="RTL"><strong>الاختبارات التي سيجريها الطبيب المعالج أثناء العلاج</strong></p><p dir="RTL">أثناء العلاج بدواء تراكلير، سينظم الطبيب المعالج مواعيد إجراء اختبارات الدم بصورة دورية، لفحص التغيرات في وظائف الكبد ومستوى الهيموجلوبين.</p><p>&nbsp;</p><p dir="RTL">بالنسبة لجميع هذه الاختبارات، يُرجى أيضاً مراجعة بطاقة تنبيهات المريض (المرفقة داخل عبوة أقراص تراكلير). من المهم أن تجري اختبارات الدم الدورية هذه طالما كنت تتناول دواء تراكلير. نقترح أن تُسجل تاريخ إجراء آخر اختبار دم في &quot;بطاقة تنبيهات المريض&quot;، وكذلك تاريخ الاختبار التالي (اسأل الطبيب عن تلك المواعيد)، وذلك لتتذكر الوقت الواجب فيه إجراء ذلك الاختبار.</p><p>&nbsp;</p><p dir="RTL"><strong><u>اختبارات الدم لوظائف الكبد</u></strong></p><p dir="RTL">تُجرى تلك الاختبارات كل شهر طوال مدة العلاج بدواء تراكلير. وينبغي إجراء اختبار إضافي بعد أسبوعين من زيادة الجرعة.</p><p>&nbsp;</p><p dir="RTL"><strong>اختبارات الدم للأنيميا</strong></p><p dir="RTL">تُجرى تلك الاختبارات شهريّاً لمدة أول أربعة شهور من العلاج، ثم كل 3 أشهر بعد ذلك، حيث يمكن أن يصاب المرضى الذين يُعالجون بدواء تراكلير بالأنيميا.</p><p>&nbsp;</p><p dir="RTL">إذا كانت تلك النتائج غير طبيعية، فقد يقرر الطبيب المعالج تخفيض الجرعة، أو إيقاف العلاج بدواء تراكلير، وإجراء اختبارات أخرى للبحث عن سبب تلك النتائج غير الطبيعية.</p><p><u>&nbsp;</u></p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا يُوصى باستخدام دواء تراكلير في علاج الأطفال المصابين بالتصلب المجموعي ومرض قرح الأصابع المستمر. يُرجى مراجعة القسم 3 أيضاً، تحت عنوان &quot;كيفية تناول دواء تراكلير&quot;.</p><p>&nbsp;</p><p dir="RTL"><strong>تراكلير والأدوية الأخرى</strong></p><p dir="RTL">يُرجى إخبار الطبيب أو الصيدلي إذا كنت تتناول حاليّاً، أو كنت تتناول مؤخراً، أي أدوية أخرى، ومن بينها الأدوية التي يتم تناولها دون وصفة طبية. ومن الأهمية بمكان أن تخبر الطبيب المعالج إذا كنت تتناول أيّاً من الأدوية التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقار سيكلوسبورين A (عقار يُستخدم بعد زراعة عضو وفي علاج الصدفية)، والذي يجب ألا يتم تناوله مع دواء تراكلير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيروليموس أو تاكروليموس هما عقاران يُستخدمان بعد عمليات زراعة الأعضاء، ولا يُوصى بتناولهما في أثناء العلاج بدواء تراكلير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; جليبنكلاميد (دواء لعلاج السكري)، أو ريفامبيسين (دواء لعلاج السل)، أو فلوكونازول (دواء مضاد للعدوى الفطرية)، أو كيتوكونازول (دواء يُستخدم في علاج متلازمة كوشينج)، أو نيفاربين (دواء لعلاج فيروس نقص المناعة البشرية (HIV))، فلا يُوصى بتناول تلك الأدوية في أثناء العلاج بدواء تراكلير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى لعلاج عدوى فيروس نقص المناعة البشرية (HIV)، مما قد يتطلب مراقبة خاصة في حالة استخدامها أثناء العلاج بدواء تراكلير.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وسائل منع الحمل الهرمونية، لا تكون فعالة في حالة استخدامها كوسيلة منع الحمل الوحيدة عند تناول تراكلير. ستجد &quot;بطاقة تنبيهات المريض&quot; داخل عبوة أقراص تراكلير، ويجب أن تقرأها بعناية. وسيحدد الطبيب المعالج و/أو طبيب أمراض النساء نوع وسيلة منع الحمل المناسبة لك.</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>الأدوية الأخرى المستخدمة في علاج ارتفاع ضغط الدم الرئوي: مثل سيلدينافيل وتادالافيل؛</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>وارفارين (مضاد التجلط)؛</p><p dir="RTL"><em>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em>سيمفاستاتين (المُستخدم في علاج ارتفاع كوليسترول الدم).</p><p>&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong></p><p dir="RTL">لا يؤثر دواء تراكلير بأي شكل في القدرة على قيادة المركبات واستخدام الآلات، أو يؤثر تأثيراً غير ملحوظ. ولكن يمكن أن يُسبب دواء تراكلير انخفاضاً في ضغط الدم، مما يجعلك تشعر بالدوار ويؤثر في الرؤية وفي القدرة على قيادة المركبات واستخدام الآلات. ولهذا، إذا شعرتَ بالدوار أو بتشويش في الرؤية في أثناء تناول تراكلير، فلا تقم بالقيادة أو تشغيل أي معدات أو آلات.</p><p>&nbsp;</p><p dir="RTL"><strong>السيدات القادرات على الإنجاب</strong></p><p dir="RTL">لا تتناولي دواء تراكلير إذا كنتِ حاملاً أو تخططين للإنجاب.</p><p>&nbsp;</p><p dir="RTL"><strong>اختبارات الحمل</strong></p><p dir="RTL">قد يضر دواء تراكلير الأجنة التي تكونت قبل البدء في العلاج، أو التي تكونت في أثناء العلاج. إذا كنتِ امرأة قادرة على الإنجاب، فسيطلب منك الطبيب المعالج إجراء اختبار حمل قبل البدء في تناول دواء تراكلير، وكذلك إجراء اختبار الحمل بصورة دورية في أثناء تناول دواء تراكلير.</p><p><em><u>&nbsp;</u></em></p><p dir="RTL"><strong>وسائل منع الحمل</strong></p><p dir="RTL">إذا كان يمكن أن تصبحي حاملاً، يجب أن تستخدمي وسيلة منع حمل موثوقة في أثناء العلاج بدواء تراكلير. سينصحكِ الطبيب المعالج أو طبيب أمراض النساء<em> </em>بخصوص وسائل منع الحمل الموثوقة المناسبة للاستخدام مع دواء تراكلير. ونظراً لأن دواء تراكلير قد يعيق فعالية وسائل منع الحمل الهرمونية (مثل وسائل منع الحمل الفموية، أو بالحقن، أو المنزرعة، أو لصقات الجلد)، فلن يكون استخدام تلك الوسيلة بمفردها آمناً. ومن ثم، إذا كنتِ تستخدمين وسائل منع الحمل الهرمونية، يجب أن تستخدمي معها وسيلة أخرى (مثل، الواقي الأنثوي، أو الحاجز المهبلي، أو الإسفنجة المانعة للحمل، أو يجب أن يستخدم الزوج أيضاً الواقي الذكري). ستجدين &quot;بطاقة تنبيهات المريض&quot; داخل عبوة أقراص تراكلير. ينبغي أن تملئي بيانات هذه البطاقة وتأخذيها إلى الطبيب المعالج في الزيارة التالية، ليتمكن الطبيب المعالج أو طبيب أمراض النساء من مساعدتك في تحديد ما إذا كنت بحاجة إلى وسيلة منع حمل إضافية أو بديلة آمنة. وينصح بإجراء اختبارات الحمل شهريّاً في أثناء تناول دواء تراكلير، وطالما كنتِ قادرة على الإنجاب.</p><p>&nbsp;</p><p dir="RTL">أخبري الطبيب على الفور إذا أصبحت حاملاً في أثناء تناول دواء تراكلير، أو كنتِ تخططين للإنجاب في المستقبل القريب.</p><p><em><u>&nbsp;</u></em></p><p dir="RTL"><strong>الرضاعة</strong></p><p dir="RTL"><strong>أخبري الطبيب المعالج</strong> على الفور <strong>إذا كنت ترضعين طفلك رضاعةً طبيعية</strong>. ويُنصح بالتوقف عن الرضاعة الطبيعية إذا وُصف لك دواء تراكلير، فليس من المعروف ما إذا كان هذا الدواء سيُفرز في لبن/ حليب الأم أم لا.</p><p>&nbsp;</p><p dir="RTL"><strong><u>الخصوبة</u></strong></p><p dir="RTL">إذا كنت رجلاً وتتناول دواء تراكلير، يحتمل أن يقل عدد الحيوانات المنوية نتيجة تناول هذا الدواء. ولا يُستبعد أن يؤثر هذا في قدرتك على الإنجاب. تحدث إلى الطبيب إذا كانت لديك أي أسئلة أو مخاوف بخصوص ذلك.</p><p dir="RTL">&nbsp;</p><p><strong><u>يحتوي تراكلير علي صوديوم</u></strong></p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم (23 ميلي غرام) لكل قرص ، أي &quot;خالٍ من الصوديوم&quot; بشكل أساسي</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب ألا يبدأ العلاج بدواء تراكلير إلا على يد طبيب خبير في علاج ارتفاع ضغط الدم الشرياني الرئوي أو التصلب المجموعي، ويجب أن يتم العلاج تحت إشرافه. احرص دومًا على تناول هذا الدواء كيفما أخبرك الطبيب المعالج تمامًا. واسأل الطبيب أو الصيدلي إذا لم تكن متأكدًا من الكيفية.</p><p>&nbsp;</p><p dir="RTL"><strong>تناول دواء تراكلير مع الطعام والشراب</strong></p><p dir="RTL">يمكن تناول دواء تراكلير مع الطعام أو دون تناول الطعام.</p><p>&nbsp;</p><p dir="RTL"><strong>الجرعة المقترحة</strong></p><p>&nbsp;</p><p dir="RTL"><strong>للمرضى البالغين</strong></p><p dir="RTL">يبدأ علاج المرضى البالغين عادةً بتناول أقراص 62.5 مليجراماً مرتين يوميّاً على مدار الأسابيع الأربعة الأولى (صباحاً ومساءً)، وبعدها سينصح الطبيب المعالج عادةً بتناول قرص 125 مليجراماً مرتين يوميّاً، بحسب كيفية تفاعل جسمك مع دواء تراكلير.</p><p>&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">تُستخدم الجرعة المقترحة بالنسبة للأطفال في علاج ارتفاع الضغط الشرياني الرئوي فقط. بالنسبة للأطفال من عمر سنة وأكبر، يبدأ العلاج بدواء تراكلير عادةً بجرعة 2 مليجرام لكل كيلو جرام من وزن الجسم مرتين يوميّاً (صباحاً ومساءً). سيحدد الطبيب المعالج الجرعة المطلوبة.</p><p>&nbsp;</p><p dir="RTL">يُرجى ملاحظة أن دواء تراكلير يتوفر أيضاً في تركيبة أقراص 32 مليجراماً قابلة للتقسيم، والتي يمكن استخدامها لتصحيح الجرعة بشكل أسهل في حالات الأطفال أو المرضى أصحاب الوزن المنخفض أو في حالات المرضى الذين يجدون صعوبة في بلع الأقراص المغلفة بطبقة رقيقة.</p><p>&nbsp;</p><p dir="RTL">إذا شعرت أن تأثير دواء تراكلير قويٌّ جداً، أو ضعيفٌ جداً، فاستشر الطبيب المعالج ليحدد ما إذا كان ينبغي تغيير الجرعة.</p><p>&nbsp;</p><p dir="RTL"><strong>كيفية تناول دواء تراكلير</strong></p><p dir="RTL">ينبغي بلع الأقراص مع الماء (صباحاً ومساءً). ويمكن تناول الأقراص مع الطعام أو دون تناول الطعام.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول جرعة أكبر من الجرعة المقررة</strong></p><p dir="RTL">إذا كنت تتناول جرعة أكبر من الجرعة التي حُددت لحالتك، فاستشر الطبيب المعالج على الفور.</p><p>&nbsp;</p><p dir="RTL"><strong>نسيان تناول دواء تراكلير</strong></p><p dir="RTL">إذا نسيت أن تتناول دواء تراكلير، فتناول جرعتك وقتما تتذكرها، ثم استمر في تناول الأقراص في المواعيد المعتادة. ولا تتناول جرعة مضاعفة لتعويض الجرعات التي نسيتها.</p><p>&nbsp;</p><p dir="RTL"><strong>التوقف عن تناول تراكلير</strong></p><p dir="RTL">قد يؤدي التوقف المفاجئ عن العلاج بدواء تراكلير إلى زيادة حدة الأعراض. فلا تتوقف عن تناول دواء تراكلير ما لم يخبرك الطبيب المعالج بذلك. فقد يطلب الطبيب تقليل الجرعة على مدار عدة أيام قبل إيقاف العلاج تمامًا.</p><p>&nbsp;</p><p dir="RTL">إذا كان لديك المزيد من الأسئلة حول استخدام هذا الدواء، فتوجه بها إلى الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يتسبب هذا الدواء في حدوث بعض الآثار الجانبية - مثله مثل جميع الأدوية الأخرى، رغم أنه لا يشعر جميع المرضى بتلك الأعراض الجانبية.</p><p>&nbsp;</p><p dir="RTL">أخطر الآثار الجانبية المرتبطة بتناول دواء تراكلير</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وظائف الكبد غير الطبيعية والتي قد يعاني منها أكثر من شخص واحد من بين كل 10 أشخاص</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأنيميا (انخفاض مستوى الهيموجلوبين في الدم) وقد يعاني منها ما يصل إلى شخص واحد من بين كل 10 أشخاص وقد تستدعي حالة الأنيميا نقل الدم في بعض الأحيان</p><p dir="RTL">يجب متابعة وظائف الكبد ومستوى الهيموجلوبين في الدم في أثناء العلاج بدواء تراكلير (انظر القسم 2). ومن الأهمية بمكان أن تُجرىَ تلك الاختبارات بحسب تعليمات الطبيب المعالج.</p><p>&nbsp;</p><p dir="RTL">من الأعراض التي تدل على أن الكبد لا يعمل جيدًا:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان (الرغبة في التقيؤ)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التقيؤ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (ارتفاع درجة الحرارة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; آلام المعدة (البطن)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصفرة (اصفرار لون البشرة أو بياض العينين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البول داكن اللون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;النعاس أو الإرهاق (شعور غير طبيعي بالتعب أو الإجهاد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض مشابهة لنزلات البرد (آلام المفاصل والعضلات مع الحمى)</p><p>&nbsp;</p><p dir="RTL">إذا لاحظت أيّاً من تلك الأعراض، <strong>فأخبر الطبيب المعالج على الفور</strong>.</p><p><u>&nbsp;</u></p><p dir="RTL"><u>الآثار الجانبية الأخرى: </u></p><p><u>&nbsp;</u></p><p dir="RTL"><strong>شائعة جداً </strong>(قد تصيب <strong>أكثر من شخص واحد من بين كل 10 </strong>أشخاص<strong>)</strong>:</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الوذمة (تورم الساقين والكاحلين، أو أي علامات أخرى على انحباس السوائل في الجسم)</p><p><u>&nbsp;</u></p><p dir="RTL"><strong>شائعة </strong>(قد تصيب <strong>ما يصل إلى شخص واحد من بين كل 10 </strong>أشخاص<strong>):</strong></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احمرار الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ردود أفعال شديدة الحساسية (مثل التهاب الجلد، والحكة، والطفح الجلدي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء الارتداد المعدي المريئي (الارتجاع المعدي المريئي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغشى (الإغماء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الخفقان (ضربات القلب السريعة أو غير المنتظمة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضغط الدم المنخفض</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; احتقان الأنف</p><p>&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تصيب <strong>ما يصل إلى شخص واحد من بين كل 100 </strong>شخص<strong>):</strong></p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة الصفيحات (انخفاض عدد الصفيحات الدموية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قلة العدلات/قلة الكريات البيضاء (انخفاض عدد كريات الدم البيضاء)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع نتائج اختبارات وظائف الكبد مع الالتهاب الكبدي (التهاب الكبد)، ويشمل ذلك تفاقم حالة التهاب كبدي كامنة&nbsp; و/أو الصفرة (اصفرار لون البشرة أو بياض العينين)</p><p>&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تصيب<strong> ما يصل إلى شخص واحد من بين كل 1000</strong> شخص):</p><p>&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحساسية (رد فعل تحسسي عام)، والوذمة الوعائية (تورم يكون في الغالب حول العينين، أو الشفتين، أو اللسان، أو الحلق)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التليف الكبدي، والفشل الكبدي (اختلال خطير في وظائف الكبد)</p><p>&nbsp;</p><p dir="RTL">تم الإبلاغ أيضًا عن حالات تشوش الرؤية، ولكن معدل تكرارها غير معلوم (يتعذر تحديد معدل التكرار من البيانات المتاحة).</p><p><strong>&nbsp;</strong></p><p dir="RTL"><strong>الآثار الجانبية بين الأطفال والمراهقين</strong></p><p dir="RTL">لا تختلف الأعراض الجانبية التي ظهرت عند علاج الأطفال بدواء تراكلير عن الأعراض الجانبية التي ظهرت بين المرضى البالغين.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>الإبلاغ عن الآثار الجانبية</strong></p><p dir="RTL">إن كان لديك أعراض جانبية أو لاحظت أعراض جانبية غير مذكورة في هذه النشرة، فضلًا ابلغ الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احتفظ بهذا الدواء بعيداً عن مرأى ومتناول الأطفال.</p><p dir="RTL">لا تستخدم هذا الدواء بعد انتهاء تاريخ الصلاحية المذكور على العبوة الكرتون بعد كلمة &quot;EXP&quot;.</p><p dir="RTL">بخصوص الزجاجات البيضاء عالية الكثافة المصنوعة من البولي إيثيلين، يجب أن تُستخدم خلال 30 يوماً من فتحها.</p><p>&nbsp;</p><p dir="RTL">لا يحفظ في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">لا تتخلص من أي دواء بإلقائه في مياه الصرف أو فضلات المنزل. اسأل الصيدلي عن كيفية التخلص من الدواء الذي لم تعد تستخدمه. فهذه الإجراءات تساعد في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مكونات دواء تراكلير</strong></p><p>&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>تراكلير أقراص مغلفة بطبقة رقيقة 125 مليجراماً:</strong> المادة الفعالة هي بوسينتان وهي مادة أحادية الهيدرات. يحتوي كل قرص على 125 مليجراماً من بوسينتان (أحادي الهيدرات).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المكونات الأخرى</strong> في قلب القرص هي نشا الذرة، ونشا مُعدل، وجليكولات نشا الصوديوم (النوع A)، وبوفيدون، وديبينات الجليسرول، وستيرات الماغنسيوم. <strong>تشتمل الطبقة الرقيقة على</strong> هايبروميلوز، وثلاثي أسيتات الغليسريل، مسحوق التلك، وثنائي أكسيد التيتانيوم (E171)، وأكسيد الحديد الأصفر (E172)، وأكسيد الحديد الأحمر (E172)، وإيثيل سيللولوز.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL" style="text-align:right"><strong>شكل دواء تراكلير ومحتويات العبوة</strong></p><p style="text-align:right"><u>&nbsp;</u></p><p dir="RTL" style="text-align:right">أقراص تراكلير المغلفة بطبقة رقيقة 125 مليجرامًا هي أقراص دائرية باللونين البرتقالي والأبيض مغلفة بطبقة رقيقة ومكتوب على أحد الجانبين &quot;125&quot;.</p><p style="text-align:right">&nbsp;</p><p dir="RTL" style="text-align:right"><strong>زجاجات بيضاء عالية الكثافة مصنوعة من البولي إيثيلين مع مادة مجففة من هلام السيلكا</strong> تحتوي على 56 قرصاً مغلفاً بطبقة رقيقة. عبوة كرتون تحتوي على 56 قرصاً مغلفاً بالفيلم (تراكلير أقراص مغلفة بطبقة رقيقة 125 مليجرامًا).</p><p dir="RTL" style="text-align:right">لا تبلع المادة المجففة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>صاحب ترخيص التسويق:</strong></p><p>أكتليون فارماسيوتيكالس ليمتد،</p><p>&nbsp;16 جيفيربشتراس،</p><p>4123 الكسفيل، سويسرا</p><p>&nbsp;</p><p><strong>المصنع:</strong></p><p>هابت فارما فولفينج جي ام بي اتش</p><p dir="RTL">بيثلنر لاندشتراس 18</p><p dir="RTL">، 31028 جروناو، ألمانيا</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            	للتواصل معنا، تفضل بزيارة الموقع الإلكتروني www.janssen.com/contact-us
	
	آخر مراجعة لهذه النشرة في 05 سبتمبر 2019

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tracleer 62.5 mg film-coated tablets

Tracleer 125 mg film-coated tablets

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tracleer 62.5 mg film-coated tablets
Each film-coated tablet contains 62.5 mg bosentan (as monohydrate).

Tracleer 125 mg film-coated tablets
Each film-coated tablet contains 125 mg bosentan (as monohydrate).

Excipient with known effect 
This medicine contains less than 1 mmol sodium (23 mg) per tablet, that is to say essentially ‘sodium-free’.

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablets):

Tracleer 62.5 mg film-coated tablets
Orange-white, round, biconvex, film-coated tablets, embossed with “62,5” on one side.

Tracleer 125 mg film-coated tablets
Orange-white, oval, biconvex, film-coated tablets, embossed with “125” on one side.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of pulmonary arterial hypertension (PAH) to improve exercise capacity and symptoms in patients with WHO functional class III. Efficacy has been shown in:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Primary (idiopathic and heritable) pulmonary arterial hypertension</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary arterial hypertension secondary to scleroderma without significant interstitial pulmonary disease</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Pulmonary arterial hypertension associated with congenital systemic-to-pulmonary shunts and Eisenmenger&rsquo;s physiology</p><p>&nbsp;</p><p>Some improvements have also been shown in patients with pulmonary arterial hypertension WHO functional class II (see section 5.1).</p><p>&nbsp;</p><p>Tracleer is also indicated to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing<strong> </strong>digital ulcer disease (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Method of administration</u></p><p>&nbsp;</p><p>Tablets are to be taken orally morning and evening, with or without food. The film-coated tablets are to be swallowed with water.</p><p>&nbsp;</p><p>Patients should be advised not to swallow the desiccant found in the white high-density polyethylene bottles.</p><p><u>&nbsp;</u></p><p><u>Posology</u></p><p><u>&nbsp;</u></p><p><u>Pulmonary arterial hypertension</u></p><p>&nbsp;</p><p>Treatment should only be initiated and monitored by a physician experienced in the treatment of PAH.</p><p>A Patient Alert Card providing important safety information that patients need to be aware of before and during treatment with Tracleer is included in the pack.</p><p>&nbsp;</p><p><em><u>Adults</u></em></p><p>In adult patients, Tracleer treatment should be initiated at a dose of 62.5&nbsp;mg twice daily for 4&nbsp;weeks and then increased to the maintenance dose of 125&nbsp;mg twice daily. The same recommendations apply to re-introduction of Tracleer after treatment interruption (see section 4.4).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>Paediatric pharmacokinetic data have shown that bosentan plasma concentrations in children with PAH aged from 1 year to 15 years were on average lower than in adult patients and were not increased by increasing the dose of Tracleer above 2 mg/kg body weight or by increasing the dosing frequency from twice daily to three times daily (see section 5.2). Increasing the dose or the dosing frequency will likely not result in additional clinical benefit.</p><p>&nbsp;</p><p>Based on these pharmacokinetic results, when used in children with PAH aged 1 year and older, the recommended starting and maintenance dose is 2 mg/kg morning and evening.</p><p>&nbsp;</p><p>In neonates with persistent pulmonary hypertension of the newborn (PPHN), the benefit of bosentan has not been shown in the standard-of-care treatment. No recommendation on a posology can be made (see sections 5.1 and 5.2).</p><p>&nbsp;</p><p><em>Management in the event of clinical deterioration of PAH</em></p><p>&nbsp;</p><p>In the event of clinical deterioration (e.g., decrease in 6-minute walk test distance by at least 10% compared with pre-treatment measurement) despite Tracleer treatment for at least 8&nbsp;weeks (target dose for at least 4&nbsp;weeks), alternative therapies should be considered. However, some patients who show no response after 8&nbsp;weeks of treatment with Tracleer may respond favourably after an additional 4 to 8&nbsp;weeks of treatment.</p><p>&nbsp;</p><p>In the event of late clinical deterioration despite treatment with Tracleer (i.e., after several months of treatment), the treatment should be re-assessed. Some patients not responding well to 125&nbsp;mg twice daily of Tracleer may slightly improve their exercise capacity when the dose is increased to 250&nbsp;mg twice daily. A careful benefit/risk assessment should be made, taking into consideration that the liver toxicity is dose dependent (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p><em>Discontinuation of treatment</em></p><p>&nbsp;</p><p>There is limited experience with abrupt discontinuation of Tracleer in patients with PAH. No evidence for acute rebound has been observed. However, to avoid the possible occurrence of harmful clinical deterioration due to potential rebound effect, gradual dose reduction (halving the dose for 3&nbsp;to&nbsp;7&nbsp;days) should be considered. Intensified monitoring is recommended during the discontinuation period.</p><p>If the decision to withdraw Tracleer is taken, it should be done gradually while an alternative therapy is introduced.</p><p>&nbsp;</p><p><u>Systemic sclerosis with ongoing digital ulcer disease</u></p><p>&nbsp;</p><p>Treatment should only be initiated and monitored by a physician experienced in the treatment of systemic sclerosis.</p><p>A Patient Alert Card providing important safety information that patients need to be aware of before and during treatment with Tracleer is included in the pack.</p><p>&nbsp;</p><p>&nbsp;</p><p><em><u>Adults</u></em></p><p>Tracleer treatment should be initiated at a dose of 62.5&nbsp;mg twice daily for 4&nbsp;weeks and then increased to the maintenance dose of 125&nbsp;mg twice daily. The same recommendations apply to re-introduction of Tracleer after treatment interruption (see section 4.4).</p><p>&nbsp;</p><p>Controlled clinical study experience in this indication is limited to 6 months (see section 5.1).</p><p>&nbsp;</p><p>The patient&rsquo;s response to treatment and need for continued therapy should be re-evaluated on a regular basis. A careful benefit/risk assessment should be made, taking into consideration the liver toxicity of bosentan (see sections 4.4 and 4.8).</p><p>&nbsp;</p><p><em><u>Paediatric population</u></em></p><p>There are no data on the safety and efficacy in patients under the age of 18&nbsp;years. Pharmacokinetic data are not available for Tracleer in young children with this disease.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p><em><u>&nbsp;</u></em></p><p>Tracleer is contraindicated in patients with moderate to severe liver dysfunction (see sections&nbsp;4.3, 4.4 and 5.2). No dose adjustment is needed in patients with mild hepatic impairment (i.e., Child-Pugh class A) (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p><em><u>&nbsp;</u></em></p><p>No dose adjustment is required in patients with renal impairment. No dose adjustment is required in patients undergoing dialysis (see section&nbsp;5.2).</p><p>&nbsp;</p><p><em>Elderly</em></p><p>&nbsp;</p><p>No dose adjustment is required in patients over the age of 65&nbsp;years.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1
•	Moderate to severe hepatic impairment, i.e., Child-Pugh class B or C (see section 5.2)
•	Baseline values of liver aminotransferases, i.e., aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT), greater than 3  the upper limit of normal (ULN; see section 4.4)
•	Concomitant use of cyclosporine A (see section 4.5)
•	Pregnancy (see sections 4.4 and 4.6)
•	Women of childbearing potential who are not using reliable methods of contraception (see sections 4.4, 4.5 and 4.6)
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The efficacy of Tracleer has not been established in patients with severe PAH. Transfer to a therapy that is recommended at the severe stage of the disease (e.g., epoprostenol) should be considered if the clinical condition deteriorates (see section&nbsp;4.2).</p><p>&nbsp;</p><p>The benefit/risk balance of bosentan has not been established in patients with WHO class I functional status of PAH.</p><p>&nbsp;</p><p>Tracleer should only be initiated if the systemic systolic blood pressure is higher than 85&nbsp;mmHg.</p><p>&nbsp;</p><p>Tracleer has not been shown to have a beneficial effect on the healing of existing digital ulcers.</p><p>&nbsp;</p><p><u>Liver function</u></p><p>&nbsp;</p><p>Elevations in liver aminotransferases, i.e., aspartate and alanine aminotransferases (AST and/or ALT), associated with bosentan are dose dependent. Liver enzyme changes typically occur within the first 26&nbsp;weeks of treatment but may also occur late in treatment (see section&nbsp;4.8). These increases may be partly due to competitive inhibition of the elimination of bile salts from hepatocytes but other mechanisms, which have not been clearly established, are probably also involved in the occurrence of liver dysfunction. The accumulation of bosentan in hepatocytes leading to cytolysis with potentially severe damage of the liver, or an immunological mechanism, are not excluded. Liver dysfunction risk may also be increased when medicinal products that are inhibitors of the bile salt export pump, e.g., rifampicin, glibenclamide and cyclosporine A (see sections 4.3 and 4.5), are co-administered with bosentan, but limited data are available.</p><p><u>&nbsp;</u></p><p><strong>Liver aminotransferase levels must be measured prior to initiation of treatment and subsequently at monthly intervals for the duration of treatment with Tracleer</strong>. <strong>In addition, liver aminotransferase levels must be measured 2&nbsp;weeks after any dose increase.</strong></p><p>&nbsp;</p><p><strong><u>Recommendations in the event of ALT/AST elevations</u></strong></p><p>&nbsp;</p><p><strong>ALT/AST levels&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment and monitoring recommendations</strong></p><p>&gt;&nbsp;3 and &pound;&nbsp;5&nbsp;&acute;&nbsp;ULN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The result should be confirmed by a second liver test; if confirmed, a decision should be made on an individual basis to continue Tracleer, possibly at a reduced dose, or to stop Tracleer administration (see section 4.2). Monitoring of aminotransferase levels should be continued at least every 2&nbsp;weeks. If the aminotransferase levels return to pre-treatment values continuing or re-introducing Tracleer according to the conditions described below should be considered.</p><p>&gt;&nbsp;5&nbsp;and &pound;&nbsp;8&nbsp;&acute;&nbsp;ULN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The result should be confirmed by a second liver test; if confirmed, treatment should be stopped and aminotransferase levels monitored at least every 2&nbsp;weeks. If the aminotransferase levels return to pre-treatment values re-introducing Tracleer according to the conditions described below should be considered.</p><p>&gt;&nbsp;8&nbsp;&acute;&nbsp;ULN&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment must be stopped and re-introduction of Tracleer is not to be considered.</p><p>&nbsp;</p><p><strong>In the event of associated clinical symptoms of liver injury</strong>,<strong> </strong>i.e., nausea, vomiting, fever, abdominal pain, jaundice, unusual lethargy or fatigue, flu-like syndrome (arthralgia, myalgia, fever),<strong> treatment must be stopped and re-introduction of Tracleer is not to be considered.</strong></p><p>&nbsp;</p><p><em><u>&nbsp;</u></em></p><p><em><u>Re-introduction of treatment</u></em></p><p>Re-introduction of treatment with Tracleer should only be considered if the potential benefits of treatment with Tracleer outweigh the potential risks and when liver aminotransferase levels are within pre-treatment values. The advice of a hepatologist is recommended. Re-introduction must follow the guidelines detailed in section&nbsp;4.2. <strong>Aminotransferase levels must then be checked within 3&nbsp;days after re-introduction, then again after a further 2&nbsp;weeks, and thereafter according to the recommendations above.</strong></p><p>ULN = upper limit of normal</p><p>&nbsp;</p><p><u>Haemoglobin concentration</u></p><p>&nbsp;</p><p>Treatment with bosentan has been associated with dose-related decreases in haemoglobin concentration (see section&nbsp;4.8). In placebo-controlled studies, bosentan-related decreases in haemoglobin concentration were not progressive, and stabilised after the first 4&ndash;12&nbsp;weeks of treatment. It is recommended that haemoglobin concentrations be checked prior to initiation of treatment, every month during the first 4 months, and quarterly thereafter. If a clinically relevant decrease in haemoglobin concentration occurs, further evaluation and investigation should be undertaken to determine the cause and need for specific treatment. In the post-marketing period, cases of anaemia requiring red blood cell transfusion have been reported (see section 4.8).</p><p>&nbsp;</p><p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>As Tracleer may render hormonal contraceptives ineffective, and taking into account the risk that pulmonary hypertension deteriorates with pregnancy as well as the teratogenic effects observed in animals:</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tracleer treatment must not be initiated in women of childbearing potential unless they practise reliable contraception and the result of the pre-treatment pregnancy test is negative</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hormonal contraceptives cannot be the sole method of contraception during treatment with Tracleer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Monthly pregnancy tests are recommended during treatment to allow early detection of pregnancy</p><p>&nbsp;</p><p>For further information see sections 4.5 and 4.6.</p><p>&nbsp;</p><p><u>Pulmonary veno-occlusive disease</u></p><p>&nbsp;</p><p>Cases of pulmonary oedema have been reported with vasodilators (mainly prostacyclins) when used in patients with pulmonary veno-occlusive disease. Consequently, should signs of pulmonary oedema occur when Tracleer is administered in patients with PAH, the possibility of associated veno-occlusive disease should be considered. In the post-marketing period there have been rare reports of pulmonary oedema in patients treated with Tracleer who had a suspected diagnosis of pulmonary veno-occlusive disease.</p><p>&nbsp;</p><p><u>Pulmonary arterial hypertension patients with concomitant left ventricular failure</u></p><p>&nbsp;</p><p>No specific study has been performed in patients with pulmonary hypertension and concomitant left ventricular dysfunction. However, 1,611 patients (804 bosentan- and 807 placebo-treated patients) with severe chronic heart failure (CHF) were treated for a mean duration of 1.5 years in a placebo-controlled study (study AC-052-301/302 [ENABLE 1 &amp; 2]). In this study there was an increased incidence of hospitalisation due to CHF during the first 4&ndash;8 weeks of treatment with bosentan, which could have been the result of fluid retention. In this study, fluid retention was manifested by early weight gain, decreased haemoglobin concentration and increased incidence of leg oedema. At the end of this study, there was no difference in overall hospitalisations for heart failure nor in mortality between bosentan- and placebo-treated patients. Consequently, it is recommended that patients be monitored for signs of fluid retention (e.g., weight gain), especially if they concomitantly suffer from severe systolic dysfunction. Should this occur, starting treatment with diuretics is recommended, or the dose of existing diuretics should be increased. Treatment with diuretics should be considered in patients with evidence of fluid retention before the start of treatment with Tracleer.</p><p>&nbsp;</p><p><u>Pulmonary arterial hypertension associated with HIV infection</u></p><p>&nbsp;</p><p>There is limited clinical study experience with the use of Tracleer in patients with PAH associated with HIV infection, treated with antiretroviral medicinal products (see section 5.1). An interaction study between bosentan and lopinavir+ritonavir in healthy subjects showed increased plasma concentrations of bosentan, with the maximum level during the first 4 days of treatment (see section 4.5). When treatment with Tracleer is initiated in patients who require ritonavir-boosted protease inhibitors, the patient&rsquo;s tolerability of Tracleer should be closely monitored with special attention, at the beginning of the initiation phase, to the risk of hypotension and to liver function tests. An increased long-term risk of hepatic toxicity and haematological adverse events cannot be excluded when bosentan is used in combination with antiretroviral medicinal products. Due to the potential for interactions related to the inducing effect of bosentan on CYP450 (see section 4.5), which could affect the efficacy of antiretroviral therapy, these patients should also be monitored carefully regarding their HIV infection.</p><p>&nbsp;</p><p><u>Pulmonary hypertension secondary to chronic obstructive pulmonary disease (COPD)</u></p><p>&nbsp;</p><p>Safety and tolerability of bosentan was investigated in an exploratory, uncontrolled 12‑week study in 11 patients with pulmonary hypertension secondary to severe COPD (stage III of GOLD classification). An increase in minute ventilation and a decrease in oxygen saturation were observed, and the most frequent adverse event was dyspnoea, which resolved with discontinuation of bosentan.</p><p>&nbsp;</p><p><u>Concomitant use with other medicinal products</u></p><p>&nbsp;</p><p>Concomitant use of Tracleer and cyclosporine A is contraindicated (see sections 4.3 and 4.5).</p><p>&nbsp;</p><p>Concomitant use of Tracleer with glibenclamide, fluconazole and rifampicin is not recommended. For further details please refer to section 4.5.</p><p>&nbsp;</p><p>Concomitant administration of both a CYP3A4 inhibitor and a CYP2C9 inhibitor with Tracleer should be avoided (see section&nbsp;4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bosentan is an inducer of the cytochrome P450 (CYP) isoenzymes CYP2C9 and CYP3A4. <em>In vitro</em> data also suggest an induction of CYP2C19. Consequently, plasma concentrations of substances metabolised by these isoenzymes will be decreased when Tracleer is co-administered. The possibility of altered efficacy of medicinal products metabolised by these isoenzymes should be considered. The dosage of these products may need to be adjusted after initiation, dose change or discontinuation of concomitant Tracleer treatment.</p><p>&nbsp;</p><p>Bosentan is metabolised by CYP2C9 and CYP3A4. Inhibition of these isoenzymes may increase the plasma concentration of bosentan (see ketoconazole). The influence of CYP2C9 inhibitors on bosentan concentration has not been studied. The combination should be used with caution.</p><p>&nbsp;</p><p><em>Fluconazole and other inhibitors of both CYP2C9 and CYP3A4: </em>Co-administration with fluconazole, which inhibits mainly CYP2C9, but to some extent also CYP3A4, could lead to large increases in plasma concentrations of bosentan. The combination is not recommended. For the same reason, concomitant administration of both a potent CYP3A4 inhibitor (such as ketoconazole, itraconazole or ritonavir) and a CYP2C9 inhibitor (such as voriconazole) with Tracleer is not recommended.</p><p>&nbsp;</p><p><em>Cyclosporine A:</em> Co-administration of Tracleer and cyclosporine A (a calcineurin inhibitor) is contraindicated (see section&nbsp;4.3). When co-administered, initial trough concentrations of bosentan were approximately 30-fold higher than those measured after bosentan alone. At steady state, bosentan plasma concentrations were 3- to 4-fold higher than with bosentan alone. The mechanism of this interaction is most likely inhibition of transport protein-mediated uptake of bosentan into hepatocytes by cyclosporine. The blood concentrations of cyclosporine A (a CYP3A4 substrate) decreased by approximately 50%. This is most likely due to induction of CYP3A4 by bosentan.</p><p>&nbsp;</p><p><em>Tacrolimus, sirolimus:</em> Co-administration of tacrolimus or sirolimus and Tracleer has not been studied in man but co-administration of tacrolimus or sirolimus and Tracleer may result in increased plasma concentrations of bosentan in analogy to co-administration with cyclosporine A. Concomitant Tracleer may reduce the plasma concentrations of tacrolimus and sirolimus. Therefore, concomitant use of Tracleer and tacrolimus or sirolimus is not advisable. Patients in need of the combination should be closely monitored for adverse events related to Tracleer and for tacrolimus and sirolimus blood concentrations.</p><p>&nbsp;</p><p><em>Glibenclamide:</em> Co-administration of bosentan 125&nbsp;mg twice daily for 5&nbsp;days decreased the plasma concentrations of<em> </em>glibenclamide (a CYP3A4 substrate) by 40%, with potential significant decrease of the hypoglycaemic effect. The plasma concentrations of bosentan were also decreased by 29%. In addition, an increased incidence of elevated aminotransferases was observed in patients receiving concomitant therapy. Both glibenclamide and bosentan inhibit the bile salt export pump, which could explain the elevated aminotransferases. This combination should not be used. No drug-drug interaction data are available with the other sulfonylureas.</p><p>&nbsp;</p><p><em>Rifampicin:</em> Co-administration in 9 healthy subjects for 7 days of bosentan 125&nbsp;mg twice daily with rifampicin, a potent inducer of CYP2C9 and CYP3A4, decreased the plasma concentrations of bosentan by 58%, and this decrease could achieve almost 90% in an individual case. As a result, a significantly reduced effect of bosentan is expected when it is co-administered with rifampicin. Concomitant use of rifampicin and Tracleer is not recommended. Data on other CYP3A4 inducers, e.g., carbamazepine, phenobarbital, phenytoin and St. John&rsquo;s wort are lacking, but their concomitant administration is expected to lead to reduced systemic exposure to bosentan. A clinically significant reduction of efficacy cannot be excluded.</p><p><em>&nbsp;</em></p><p><em>Lopinavir+ritonavir (and other ritonavir-boosted protease inhibitors): </em>Co-administration of bosentan 125 mg twice daily and lopinavir+ritonavir 400+100 mg twice daily for 9.5 days in healthy volunteers resulted in initial trough plasma concentrations of bosentan that were approximately 48-fold higher than those measured after bosentan administered alone. On day 9, plasma concentrations of bosentan were approximately 5-fold higher than with bosentan administered alone. Inhibition by ritonavir of transport protein-mediated uptake into hepatocytes and of CYP3A4, thereby reducing the clearance of bosentan, most likely causes this interaction. When administered concomitantly with lopinavir+ritonavir, or other ritonavir-boosted protease inhibitors, the patient&rsquo;s tolerability of Tracleer should be monitored.</p><p>&nbsp;</p><p>After co-administration of bosentan for 9.5 days, the plasma exposures to lopinavir and ritonavir decreased to a clinically non-significant extent (by approximately 14% and 17%, respectively). However, full induction by bosentan might not have been reached and a further decrease of protease inhibitors cannot be excluded. Appropriate monitoring of the HIV therapy is recommended. Similar effects would be expected with other ritonavir-boosted protease inhibitors (see section 4.4).</p><p>&nbsp;</p><p><em>Other antiretroviral agents:</em> No specific recommendation can be made with regard to other available antiretroviral agents due to the lack of data. Due to the marked hepatotoxicity of nevirapine, which could add to bosentan liver toxicity, this combination is not recommended.</p><p><em>Hormonal contraceptives: </em>Co-administration of bosentan 125&nbsp;mg twice daily for 7 days with a single dose of oral contraceptive containing norethisterone 1&nbsp;mg + ethinyl estradiol 35&nbsp;mcg decreased the AUC of norethisterone and ethinyl estradiol by 14% and 31%, respectively. However, decreases in exposure were as much as 56% and 66%, respectively, in individual subjects. Therefore, hormone-based contraceptives alone, regardless of the route of administration (i.e., oral, injectable, transdermal or implantable forms), are not considered as reliable methods of contraception (see sections 4.4 and 4.6).</p><p>&nbsp;</p><p><em>Warfarin:</em> Co-administration of bosentan 500&nbsp;mg twice daily for 6&nbsp;days decreased the plasma concentrations of both S-warfarin (a CYP2C9 substrate) and R-warfarin (a CYP3A4 substrate) by 29% and 38%, respectively. Clinical experience with concomitant administration of bosentan with warfarin in patients with PAH did not result in clinically relevant changes in International Normalized Ratio (INR) or warfarin dose (baseline versus end of the clinical studies). In addition, the frequency of changes in warfarin dose during the studies due to changes in INR or due to adverse events was similar among bosentan- and placebo-treated patients. No dose adjustment is needed for warfarin and similar oral anticoagulant agents when bosentan is initiated, but intensified monitoring of INR is recommended, especially during bosentan initiation and the up-titration period.</p><p>&nbsp;</p><p><em>Simvastatin:</em> Co-administration of bosentan 125&nbsp;mg twice daily for 5&nbsp;days decreased the plasma concentrations of<em> </em>simvastatin (a CYP3A4 substrate) and its active b‑hydroxy acid metabolite by 34% and 46%, respectively. The plasma concentrations of bosentan were not affected by concomitant simvastatin. Monitoring of cholesterol levels and subsequent dosage adjustment should be considered.</p><p>&nbsp;</p><p><em>Ketoconazole:</em> Co-administration for 6&nbsp;days of bosentan 62.5&nbsp;mg twice daily with ketoconazole, a potent CYP3A4 inhibitor, increased the plasma concentrations of bosentan approximately 2‑fold. No dose adjustment of Tracleer is considered necessary. Although not demonstrated through <em>in vivo</em> studies, similar increases in bosentan plasma concentrations are expected with the other potent CYP3A4 inhibitors (such as itraconazole or ritonavir). However, when combined with a CYP3A4 inhibitor, patients who are poor metabolisers of CYP2C9 are at risk of increases in bosentan plasma concentrations that may be of higher magnitude, thus leading to potential harmful adverse events.</p><p>&nbsp;</p><p><em>Epoprostenol:</em> Limited<strong> </strong>data obtained from a study (AC-052-356 [BREATHE-3]) in which 10&nbsp;paediatric patients received the combination of bosentan and epoprostenol indicate that after both single- and multiple-dose administration, the C<sub>max</sub> and AUC values of bosentan were similar in patients with or without continuous infusion of epoprostenol (see section 5.1).</p><p>&nbsp;</p><p><em>Sildenafil:</em><strong> </strong>Co-administration of bosentan 125&nbsp;mg twice daily (steady state) with sildenafil 80 mg three times a day (at steady state) concomitantly administered during 6 days in healthy volunteers resulted in a 63% decrease in the sildenafil AUC and a 50% increase in the bosentan AUC. Caution is recommended in the case of co-administration.</p><p>&nbsp;</p><p><em>Tadalafil:</em> Bosentan (125 mg twice daily) reduced tadalafil (40 mg once per day) systemic exposure by 42% and C<sub>max</sub> by 27% following multiple dose co-administration. Tadalafil did not affect the exposure (AUC and C<sub>max</sub>) of bosentan or its metabolites.<strong><u> </u></strong></p><p>&nbsp;</p><p><em>Digoxin:</em> Co-administration for 7&nbsp;days of bosentan 500&nbsp;mg twice daily with digoxin decreased the AUC, C<sub>max </sub>and C<sub>min </sub>of digoxin by 12%, 9% and 23%, respectively. The mechanism for this interaction may be induction of P‑glycoprotein. This interaction is unlikely to be of clinical relevance.</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p>Interaction studies have only been performed in adults.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>&nbsp;</p><p>Studies in animals have shown reproductive toxicity (teratogenicity, embryotoxicity; see section&nbsp;5.3). There are no reliable data on the use of Tracleer in pregnant women. The potential risk for humans is still unknown. Tracleer is contraindicated in pregnancy (see section&nbsp;4.3).</p><p><u>&nbsp;</u></p><p><u>Women of childbearing potential</u></p><p>&nbsp;</p><p>Before the initiation of Tracleer treatment in women of childbearing potential, the absence of pregnancy should be checked, appropriate advice on reliable methods of contraception provided, and reliable contraception initiated. Patients and prescribers must be aware that due to potential pharmacokinetic interactions, Tracleer may render hormonal contraceptives ineffective (see section&nbsp;4.5). Therefore, women of childbearing potential must not use hormonal contraceptives (including oral, injectable, transdermal or implantable forms) as the sole method of contraception but must use an additional or an alternative reliable method of contraception. If there is any doubt about what contraceptive advice should be given to the individual patient, consultation with a gynaecologist is recommended. Because of possible hormonal contraception failure during Tracleer treatment, and also bearing in mind the risk that pulmonary hypertension severely deteriorates with pregnancy, monthly pregnancy tests during treatment with Tracleer are recommended to allow early detection of pregnancy.</p><p><u>&nbsp;</u></p><p><u>Breast-feeding</u></p><p>&nbsp;</p><p>It is not known whether bosentan is excreted into human breast milk. Breast-feeding is not recommended during treatment with Tracleer.</p><p><u>&nbsp;</u></p><p><u>Fertility</u></p><p><u>&nbsp;</u></p><p>Animal studies showed testicular effects (see section 5.3). In a study investigating the effects of bosentan on testicular function in male PAH patients, 8 out of 24 patients showed a decreased sperm concentration from baseline of at least 42% after 3 or 6 months of treatment with bosentan. Based on these findings and preclinical data, it cannot be excluded that bosentan may have a detrimental effect on spermatogenesis in men. In male children, a long-term impact on fertility after treatment with bosentan cannot be excluded.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific studies have been conducted to assess the direct effect of Tracleer on the ability to drive and use machines. However, Tracleer may induce hypotension, with symptoms of dizziness, blurred vision or syncope that could affect the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In 20 placebo-controlled studies, conducted in a variety of therapeutic indications, a total of 2,486 patients were treated with bosentan at daily doses ranging from 100 mg to 2000 mg and 1,838 patients were treated with placebo. The mean treatment duration was 45 weeks. Adverse reactions were defined as events occurring in at least 1% of patients on bosentan and at a frequency at least 0.5% more than on placebo. The most frequent adverse reactions are headache (11.5%), oedema / fluid retention (13.2%), abnormal liver function test (10.9%) and anaemia / haemoglobin decrease (9.9%).</p><p>&nbsp;</p><p>Treatment with bosentan has been associated with dose-dependent elevations in liver aminotransferases and decreases in haemoglobin concentration (see section 4.4).</p><p>&nbsp;</p><p>Adverse reactions observed in 20 placebo-controlled studies and post-marketing experience with bosentan<strong> </strong>are ranked according to frequency using the following convention: very common (&sup3; 1/10); common (&sup3;1/100 to &lt; 1/10); uncommon (&sup3;&nbsp;1/1,000 to &lt; 1/100); rare (&sup3; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).<s> </s></p><p>&nbsp;</p><p>Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness. No clinically relevant differences in adverse reactions were observed between the overall dataset and the approved indications.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Anaemia, haemoglobin decrease, (see section&nbsp;4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Anaemia or haemoglobin decreases requiring red blood cell transfusion<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Thrombocytopenia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Neutropenia, leukopenia<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypersensitivity reactions (including dermatitis, pruritus and rash)<sup>2</sup></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylaxis and/or angioedema<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Headache<sup>3</sup></p></td></tr><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Syncope<sup>1, 4</sup></p></td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Blurred vision<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Palpitations<sup>1, 4</sup></p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Flushing</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hypotension<sup>1, 4</sup></p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Nasal congestion<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Gastrooesophageal reflux disease</p><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Very common</p></td><td style="vertical-align:top"><p>Abnormal liver function test (see section&nbsp;4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Aminotransferase elevations associated with hepatitis (including&nbsp;possible exacerbation of underlying hepatitis) and/or jaundice<sup>1</sup> (see section&nbsp;4.4)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Liver cirrhosis, liver failure<sup>1</sup></p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Erythema</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Very common</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Oedema, fluid retention<sup>5</sup></p><p>&nbsp;</p></td></tr></tbody></table><p><sup>1</sup> Data derived from post-marketing experience, frequencies based on statistical modelling of placebo-controlled</p><p>&nbsp;&nbsp;clinical trial data.</p><p><sup>2</sup> Hypersensitivity reactions were reported in 9.9% of patients on bosentan and 9.1% of patients on placebo.</p><p><sup>3 </sup>Headache was reported in 11.5% of patients on bosentan and 9.8% of patients on placebo.</p><p><sup>4</sup> These types of reactions can also be related to the underlying disease.</p><p><sup>5 </sup>Oedema or fluid retention was reported in 13.2% of patients on bosentan and 10.9% of patients on placebo.</p><p>&nbsp;</p><p>In the post-marketing period rare cases of unexplained hepatic cirrhosis were reported after prolonged therapy with Tracleer in patients with multiple co-morbidities and therapies with medicinal products. There have also been rare reports of liver failure. These cases reinforce the importance of strict adherence to the monthly schedule for monitoring of liver function for the duration of treatment with Tracleer (see section 4.4).</p><p><u>&nbsp;</u></p><p><u>Paediatric population</u></p><p><u>&nbsp;</u></p><p><em>Uncontrolled clinical studies in paediatric patients</em></p><p>&nbsp;</p><p>The safety profile in the first paediatric uncontrolled study performed with the film-coated tablet (BREATHE-3: n&nbsp;=&nbsp;19, median age 10 years [range 3&ndash;15 years], open-label bosentan 2 mg/kg twice daily; treatment duration 12 weeks) was similar to that observed in the pivotal trials in adult patients with PAH. In BREATHE-3, the most frequent adverse reactions were flushing (21%), headache, and abnormal liver function test (each 16%).</p><p>&nbsp;</p><p>A pooled analysis of uncontrolled paediatric studies conducted in PAH with the bosentan 32 mg dispersible tablet formulation (FUTURE 1/2, FUTURE 3/Extension) included a total of 100 children treated with bosentan 2 mg/kg twice daily (n = 33), 2 mg/kg three times daily (n = 31), or 4 mg/kg twice daily (n = 36). At enrolment, six patients were between 3 months and 1 year old, 15 children were between 1 and less than 2 years old, and 79 were between 2 and 12 years old. The median treatment duration was 71.8 weeks (range 0.4&ndash;258 weeks).</p><p>&nbsp;</p><p>The safety profile in this pooled analysis of uncontrolled paediatric studies was similar to that observed in the pivotal trials in adult patients with PAH except for infections, which were more frequently reported than in adults (69.0% vs 41.3%). This difference in infection frequency may in part be due to the longer median treatment exposure in the paediatric set (median 71.8 weeks) compared with the adult set (median 17.4 weeks). The most frequent adverse events were upper respiratory tract infections (25%), pulmonary (arterial) hypertension (20%), nasopharyngitis (17%), pyrexia (15%), vomiting (13%), bronchitis (10%), abdominal pain (10%), and diarrhoea (10%). There was no relevant difference in adverse event frequencies between patients above and below the age of 2 years; however, this is based on only 21 children less than 2 years, including 6 patients between 3 months to 1 year of age. Adverse events of liver abnormalities and anaemia/haemoglobin decrease occurred in 9% and 5% of patients, respectively.</p><p>&nbsp;</p><p>In a randomised placebo-controlled study, conducted in PPHN patients (FUTURE-4), a total of 13 neonates were treated with the bosentan dispersible tablet formulation at a dose of 2 mg/kg twice daily (8 patients were on placebo). The median bosentan and placebo treatment duration was, respectively, 4.5 days (range 0.5&ndash;10.0 days) and 4.0 days (range 2.5&ndash;6.5 days). The most frequent adverse events in the bosentan- and placebo-treated patients were, respectively, anaemia or haemoglobin decrease (7 and 2 patients), generalised oedema (3 and 0 patients), and vomiting (2 and 0 patients).</p><p><u>&nbsp;</u></p><p><u>Laboratory abnormalities</u></p><p>&nbsp;</p><p><em>Liver test abnormalities</em></p><p><em>&nbsp;</em></p><p>In the clinical programme, dose-dependent elevations in liver aminotransferases generally occurred within the first 26&nbsp;weeks of treatment, usually developed gradually, and were mainly asymptomatic. In the post-marketing period rare cases of liver cirrhosis and liver failure have been reported.</p><p>&nbsp;</p><p>The mechanism of this adverse effect is unclear. These elevations in aminotransferases may reverse spontaneously while continuing treatment with the maintenance dose of Tracleer or after dose reduction, but interruption or cessation may be necessary (see section&nbsp;4.4).</p><p>In the 20 integrated placebo-controlled studies, elevations in liver aminotransferases &sup3; 3&nbsp;&acute;ULN were observed in 11.2% of the bosentan-treated patients as compared to 2.4% of the placebo-treated patients. Elevations to &sup3;&nbsp;8&nbsp;&acute;&nbsp;ULN were seen in 3.6% of the bosentan-treated patients and 0.4% of the placebo-treated patients. Elevations in aminotransferases were associated with elevated bilirubin (&sup3;&nbsp;2&nbsp;&acute;&nbsp;ULN) without evidence of biliary obstruction in 0.2% (5&nbsp;patients) on bosentan and 0.3% (6&nbsp;patients) on placebo.</p><p>&nbsp;</p><p>In the pooled analysis of 100 PAH children from uncontrolled paediatric studies FUTURE 1/2 and FUTURE 3/Extension, elevations in liver aminotransferases &ge; 3 &acute; ULN were observed in 2% of patients.</p><p>&nbsp;</p><p>In the FUTURE-4 study including 13 neonates with PPHN treated with bosentan 2 mg/kg twice daily for less than 10 days (range 0.5&ndash;10.0 days), there were no cases of liver aminotransferases &ge; 3 &acute; ULN during treatment, but one case of hepatitis occurred 3 days after the end of bosentan treatment.</p><p>&nbsp;</p><p><em>Haemoglobin</em></p><p>&nbsp;</p><p>In the adult placebo-controlled studies, a decrease in haemoglobin concentration to below&nbsp;10&nbsp;g/dL from baseline was reported in 8.0% of bosentan-treated patients and 3.9% of placebo-treated patients (see section 4.4).</p><p>&nbsp;</p><p>In the pooled analysis of 100 PAH children from uncontrolled paediatric studies FUTURE 1/2 and FUTURE 3/Extension, a decrease in haemoglobin concentration from baseline to below 10 g/dL was reported in 10.0% of patients. There was no decrease to below 8 g/dL.</p><p>&nbsp;</p><p>In the FUTURE-4 study, 6 out of 13 bosentan-treated neonates with PPHN experienced a decrease in haemoglobin from within the reference range at baseline to below the lower limit of normal during the treatment.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system listed in Appendix V.</p><p><u>To reports any side effect(s):</u></p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia: </strong></p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance Centre (NPC):</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; SFDA Call Center: 19999</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: https://ade.sfda.gov.sa/</p><p><strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC States:</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Bosentan has been administered as a single dose of up to 2,400&nbsp;mg to healthy subjects and up to 2,000&nbsp;mg/day for 2&nbsp;months in patients with a disease other than pulmonary hypertension. The most common adverse reaction was headache of mild to moderate intensity.</p><p>&nbsp;</p><p>Massive overdose may result in pronounced hypotension requiring active cardiovascular support. In the post-marketing period there was one reported overdose of 10,000 mg of Tracleer taken by an adolescent male patient. He had symptoms of nausea, vomiting, hypotension, dizziness, sweating and blurred vision. He recovered completely within 24 hours with blood pressure support. Note: bosentan is not removed through dialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: other antihypertensives, ATC code: C02KX01</p><p>&nbsp;</p><p><u>Mechanism of action</u></p><p>&nbsp;</p><p>Bosentan is a dual endothelin receptor antagonist (ERA) with affinity for both endothelin A and B (ET<sub>A</sub> and ET<sub>B</sub>) receptors. Bosentan decreases both pulmonary and systemic vascular resistance resulting in increased cardiac output without increasing heart rate.</p><p>&nbsp;</p><p>The neurohormone endothelin-1 (ET-1) is one of the most potent vasoconstrictors known and can also promote fibrosis, cell proliferation, cardiac hypertrophy and remodelling, and is pro-inflammatory. These effects are mediated by endothelin binding to ET<sub>A</sub> and ET<sub>B</sub> receptors located in the endothelium and vascular smooth muscle cells. ET-1 concentrations in tissues and plasma are increased in several cardiovascular disorders and connective tissue diseases, including PAH, scleroderma, acute and chronic heart failure, myocardial ischaemia, systemic hypertension and atherosclerosis, suggesting a pathogenic role of ET-1 in these diseases. In PAH and heart failure, in the absence of endothelin receptor antagonism, elevated ET-1 concentrations are strongly correlated with the severity and prognosis of these diseases.</p><p>&nbsp;</p><p>Bosentan competes with the binding of ET-1 and other ET peptides to both ET<sub>A</sub> and ET<sub>B</sub> receptors, with a slightly higher affinity for ET<sub>A</sub> receptors (K<sub>i</sub>&nbsp;=&nbsp;4.1&ndash;43&nbsp;nanomolar) than for ET<sub>B</sub> receptors (K<sub>i</sub>&nbsp;=&nbsp;38&ndash;730&nbsp;nanomolar). Bosentan specifically antagonises ET receptors and does not bind to other receptors.</p><p>&nbsp;</p><p><u>Efficacy</u></p><p>&nbsp;</p><p><em>Animal models</em></p><p>In animal models of pulmonary hypertension, chronic oral administration of bosentan reduced pulmonary vascular resistance and reversed pulmonary vascular and right ventricular hypertrophy. In an animal model of pulmonary fibrosis, bosentan reduced collagen deposition in the lungs.</p><p>&nbsp;</p><p><em>Efficacy in adult patients with pulmonary arterial hypertension</em></p><p>Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted in 32 (study AC-052-351) and 213 (study AC-052-352 [BREATHE-1]) adult patients with WHO functional class&nbsp;III&ndash;IV PAH (primary pulmonary hypertension or pulmonary hypertension secondary mainly to scleroderma). After 4&nbsp;weeks of bosentan 62.5&nbsp;mg twice daily, the maintenance doses studied in these studies were 125&nbsp;mg twice daily in AC‑052-351, and 125&nbsp;mg twice daily and 250&nbsp;mg twice daily in AC-052-352.</p><p>&nbsp;</p><p>Bosentan was added to patients&rsquo; current therapy, which could include a combination of anticoagulants, vasodilators (e.g., calcium channel blockers), diuretics, oxygen and digoxin, but not epoprostenol. Control was placebo plus current therapy.</p><p>&nbsp;</p><p>The primary endpoint for each study was change in 6-minute walk distance at 12&nbsp;weeks for the first study and 16&nbsp;weeks for the second study. In both studies, treatment with bosentan resulted in significant increases in exercise capacity. The placebo-corrected increases in walk distance compared with baseline were 76&nbsp;metres (p&nbsp;=&nbsp;0.02; t-test) and 44&nbsp;metres (p&nbsp;=&nbsp;0.0002; Mann-Whitney U test) at the primary endpoint of each study, respectively. The differences between the two groups, 125&nbsp;mg twice daily and 250&nbsp;mg twice daily, were not statistically significant but there was a trend towards improved exercise capacity in the group treated with 250&nbsp;mg twice daily.</p><p>&nbsp;</p><p>The improvement in walk distance was apparent after 4&nbsp;weeks of treatment, was clearly evident after 8&nbsp;weeks of treatment and was maintained for up to 28&nbsp;weeks of double-blind treatment in a subset of the patient population.</p><p>&nbsp;</p><p>In a retrospective responder analysis based on change in walking distance, WHO functional class and dyspnoea of the 95 patients randomised to bosentan 125&nbsp;mg twice daily in the placebo-controlled studies, it was found that at week 8, 66 patients had improved, 22 were stable and 7 had deteriorated. Of the 22 patients stable at week 8, 6 improved at week 12/16 and 4 deteriorated compared with baseline. Of the 7 patients who deteriorated at week 8, 3 improved at week 12/16 and 4 deteriorated compared with baseline.</p><p>&nbsp;</p><p>Invasive haemodynamic parameters were assessed in the first study only. Treatment with bosentan led to a significant increase in cardiac index associated with a significant reduction in pulmonary artery pressure, pulmonary vascular resistance and mean right atrial pressure.</p><p>&nbsp;</p><p>A reduction in symptoms of PAH was observed with bosentan treatment. Dyspnoea measurement during walk tests showed an improvement in bosentan-treated patients. In the AC‑052-352 study, 92% of the 213 patients were classified at baseline as WHO functional class&nbsp;III and 8% as class&nbsp;IV. Treatment with bosentan led to a WHO functional class improvement in 42.4% of patients (placebo 30.4%). The overall change in WHO functional class during both studies was significantly better among bosentan-treated patients as compared with placebo-treated patients. Treatment with bosentan was associated with a significant reduction in the rate of clinical worsening compared with placebo at 28&nbsp;weeks (10.7% vs 37.1%, respectively; p&nbsp;=&nbsp;0.0015).</p><p>&nbsp;</p><p>In a randomised, double-blind, multi-centre, placebo-controlled study (AC-052-364 [EARLY]), 185&nbsp;PAH patients in WHO functional class II (mean baseline 6-minute walk distance of 435 metres) received bosentan 62.5 mg twice daily for 4 weeks followed by 125 mg twice daily (n = 93), or placebo (n = 92) for 6 months. Enrolled patients were PAH-treatment-na&iuml;ve (n = 156) or on a stable dose of sildenafil (n = 29). The co-primary endpoints were percentage change from baseline in pulmonary vascular resistance (PVR) and change from baseline in 6-minute walk distance to Month 6 versus placebo. The table below illustrates the pre-specified protocol analyses.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:640px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>PVR (dyn.sec/cm<sup>5</sup>)</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>6-Minute Walk Distance (m)</strong></p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Placebo (n=88)</p></td><td style="vertical-align:top"><p>Bosentan (n=80)</p></td><td style="vertical-align:top"><p>Placebo (n=91)</p></td><td style="vertical-align:top"><p>Bosentan (n=86)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline (BL); mean (SD)</p></td><td style="vertical-align:top"><p>802 (365)</p></td><td style="vertical-align:top"><p>851 (535)</p></td><td style="vertical-align:top"><p>431 (92)</p></td><td style="vertical-align:top"><p>443 (83)</p></td></tr><tr><td style="vertical-align:top"><p>Change from BL; mean (SD)</p></td><td style="vertical-align:top"><p>128 (465)</p></td><td style="vertical-align:top"><p>-69 (475)</p></td><td style="vertical-align:top"><p>-8 (79)</p></td><td style="vertical-align:top"><p>11 (74)</p></td></tr><tr><td style="vertical-align:top"><p>Treatment effects</p></td><td colspan="2" style="vertical-align:top"><p>-22.6%</p></td><td colspan="2" style="vertical-align:top"><p>19</p></td></tr><tr><td style="vertical-align:top"><p>95% CL</p></td><td colspan="2" style="vertical-align:top"><p>-34, -10</p></td><td colspan="2" style="vertical-align:top"><p>-4, 42</p></td></tr><tr><td style="vertical-align:top"><p>P-value</p></td><td colspan="2" style="vertical-align:top"><p>&lt; 0.0001</p></td><td colspan="2" style="vertical-align:top"><p>0.0758</p></td></tr></tbody></table><p>CL = confidence limit; PVR = pulmonary vascular resistance; SD = standard deviation.</p><p>&nbsp;</p><p>Treatment with bosentan was associated with a reduction in the rate of clinical worsening, defined as a composite of symptomatic progression, hospitalisation for PAH and death, compared with placebo (proportional risk reduction 77%, 95% confidence interval [CI] 20&ndash;94%, p = 0.0114). The treatment effect was driven by improvement in the component symptomatic progression. There was one hospitalisation related to PAH worsening in the bosentan group and three hospitalisations in the placebo group. Only one death occurred in each treatment group during the 6-month double-blind study period, therefore no conclusion can be drawn on survival.</p><p>&nbsp;</p><p>Long-term data were generated from all 173&nbsp;patients who were treated with bosentan in the controlled phase and/or were switched from placebo to bosentan in the open-label extension phase of the EARLY study. The mean duration of exposure to bosentan treatment was 3.6&nbsp;&plusmn;&nbsp;1.8&nbsp;years (up to 6.1&nbsp;years), with 73% of patients treated for at least 3&nbsp;years and 62% for at least 4&nbsp;years. Patients could receive additional PAH treatment as required in the open-label extension. The majority of patients were diagnosed with idiopathic or heritable PAH (61%). Overall, 78% of patients remained in WHO functional class II. Kaplan-Meier estimates of survival were 90% and 85% at 3 and 4 years after the start of treatment, respectively. At the same timepoints, 88% and 79% of patients remained free from PAH worsening (defined as all-cause death, lung transplantation, atrial septostomy or start of intravenous or subcutaneous prostanoid treatment). The relative contributions of previous placebo treatment in the double-blind phase and of other medications started during the open-label extension period are unknown.</p><p>&nbsp;</p><p>In a prospective, multi-centre, randomised, double-blind, placebo-controlled study (AC-052-405 [BREATHE-5]), patients with PAH WHO functional class III and Eisenmenger physiology associated with congenital heart disease received bosentan 62.5 mg twice daily for 4 weeks, then 125 mg twice daily for a further 12 weeks (n&nbsp;=&nbsp;37, of whom 31 had a predominantly right to left, bidirectional shunt). The primary objective was to show that bosentan did not worsen hypoxaemia. After 16 weeks, the mean oxygen saturation was increased in the bosentan group by 1.0% (95% CI &ndash;0.7%&ndash;2.8%) as compared to the placebo group (n&nbsp;=&nbsp;17), showing that bosentan did not worsen hypoxaemia. The mean pulmonary vascular resistance was significantly reduced in the bosentan group (with a predominant effect observed in the subgroup of patients with bidirectional intracardiac shunt). After 16 weeks, the mean placebo-corrected increase in 6-minute walk distance was 53&nbsp;metres (p&nbsp;=&nbsp;0.0079), reflecting improvement in exercise capacity. Twenty-six patients continued to receive bosentan in the 24-week open-label extension phase (AC-052-409) of the BREATHE-5 study (mean duration of treatment = 24.4 &plusmn; 2.0 weeks) and, in general, efficacy was maintained.</p><p>&nbsp;</p><p>An open-label, non-comparative study (AC-052-362 [BREATHE-4]) was performed in 16 patients with WHO functional class III PAH associated with HIV infection. Patients were treated with bosentan 62.5&nbsp;mg twice daily for 4 weeks followed by 125 mg twice daily for a further 12 weeks. After 16&nbsp;weeks&rsquo; treatment, there were significant improvements from baseline in exercise capacity: the mean increase in 6-minute walk distance was 91.4 metres from 332.6 metres on average at baseline (p &lt; 0.001). No formal conclusion can be drawn regarding the effects of bosentan on antiretroviral drug efficacy (see also section 4.4).</p><p>&nbsp;</p><p>There are no studies to demonstrate beneficial effects of Tracleer treatment on survival. However, long-term vital status was recorded for all 235 patients who were treated with bosentan in the two pivotal placebo-controlled studies (AC-052-351 and AC-052-352) and/or their two uncontrolled, open-label extensions. The mean duration of exposure to bosentan was 1.9 years &plusmn; 0.7 years (min: 0.1&nbsp;years; max: 3.3 years) and patients were observed for a mean of 2.0 &plusmn; 0.6 years. The majority of patients were diagnosed as primary pulmonary hypertension (72%) and were in WHO functional class III (84%). In this total population, Kaplan-Meier estimates of survival were 93% and 84% 1 and 2 years after the start of treatment with bosentan, respectively. Survival estimates were lower in the subgroup of patients with PAH secondary to systemic sclerosis. The estimates may have been influenced by the initiation of epoprostenol treatment in 43/235 patients.</p><p>&nbsp;</p><p><em>Studies performed in children with pulmonary arterial hypertension</em></p><p>&nbsp;</p><p>BREATHE-3 (AC-052-356)</p><p>Bosentan film-coated tablets were evaluated in an open-label uncontrolled study in 19 paediatric patients with PAH aged 3 to 15 years. This study was primarily designed as a pharmacokinetic study (see section 5.2). Patients had primary pulmonary hypertension (10 patients) or PAH related to congenital heart diseases (9 patients) and were in WHO functional class II (n = 15, 79%) or class III (n = 4, 21%) at baseline. Patients were divided into three body-weight groups and dosed with bosentan at approximately 2 mg/kg twice daily for 12 weeks. Half of the patients in each group were already being treated with intravenous epoprostenol and the dose of epoprostenol remained constant for the duration of the study.</p><p>&nbsp;</p><p>Haemodynamics were measured in 17 patients. The mean increase from baseline in cardiac index was 0.5&nbsp;L/min/m<sup>2</sup>, the mean decrease in mean pulmonary arterial pressure was 8 mmHg, and the mean decrease in PVR was 389 dyn&middot;sec&middot;cm<sup>-5</sup>.<em> </em>These haemodynamic improvements from baseline were similar with or without co-administration of epoprostenol. Changes in exercise test parameters at week 12 from baseline were highly variable and none were significant.</p><p>&nbsp;</p><p>FUTURE 1/2 (AC-052-365/AC-052-367)</p><p>FUTURE 1 was an open-label, uncontrolled study that was conducted with the dispersible tablet formulation of bosentan administered at a maintenance dose of 4 mg/kg twice daily to 36 patients from 2 to 11 years of age. It was primarily designed as a pharmacokinetic study (see section 5.2). At baseline, patients had idiopathic (31 patients [86%]) or familial (5 patients [14%]) PAH, and were in WHO functional class II (n = 23, 64%) or class III (n = 13, 36%). In the FUTURE 1 study, the median exposure to study treatment was 13.1 weeks (range: 8.4 to 21.1). 33 of these patients were provided with continued treatment with bosentan dispersible tablets at a dose of 4 mg/kg twice daily in the FUTURE 2 uncontrolled extension phase for a median overall treatment duration of 2.3 years (range: 0.2 to 5.0 years). At baseline in FUTURE 1, 9 patients were taking epoprostenol. 9 patients were newly initiated on PAH-specific medication during the study. The Kaplan-Meier event-free estimate for worsening of PAH (death, lung transplantation, or hospitalisation for PAH worsening) at 2 years was 78.9%. The Kaplan-Meier estimate of overall survival at 2 years was 91.2%.</p><p>&nbsp;</p><p>FUTURE 3 (AC-052-373)</p><p>In this open-label randomised study with the bosentan 32 mg dispersible tablet formulation, 64 children with stable PAH from 3 months to 11 years of age were randomised to 24 weeks&rsquo; bosentan treatment 2&nbsp;mg/kg twice daily (n = 33) or 2&nbsp;mg/kg three times daily (n = 31). 43 (67.2%) were &ge; 2 years to 11 years old, 15 (23.4%) were between 1 and 2 years old, and 6 (9.4%) were between 3 months and 1 year old. The study was primarily designed as a pharmacokinetic study (see section 5.2), and efficacy endpoints were only exploratory. The aetiology of PAH, according to Dana Point classification, included idiopathic PAH (46%), heritable PAH (3%), associated PAH after corrective cardiac surgery (38%), and PAH related to congenital heart disease associated with systemic-to-pulmonary shunts, including Eisenmenger syndrome (13%). Patients were in WHO functional class I (n = 19, 29 %), class II (n = 27, 42%) or class III (n = 18, 28%) at start of study treatment. At study entry, patients were treated with PAH medications (most frequently phosphodiesterase type-5 inhibitor [sildenafil] alone [35.9%], bosentan alone [10.9%], and a combination of bosentan, iloprost, and sildenafil [10.9%]) and continued their PAH treatment during the study.</p><p>&nbsp;</p><p>At study start, less than half of the patients included (45.3% [29/64]) had bosentan treatment alone not combined with other PAH medication. 40.6% (26/64) remained on bosentan monotherapy during the 24 weeks of study treatment without experiencing PAH worsening. The analysis on the global population included (64 patients) showed that the majority had remained at least stable (i.e., without deterioration) based on non-paediatric-specific WHO functional class assessment (97% twice daily, 100% three times daily) and physician&rsquo;s global clinical impression (94% twice daily, 93% three times daily) during the treatment period. The Kaplan-Meier event-free estimate for worsening of PAH (death, lung transplantation, or hospitalisation for PAH worsening) at 24 weeks was 96.9% and 96.7% in the twice daily and three times daily groups, respectively.</p><p>&nbsp;</p><p>There was no evidence of any clinical benefit with 2 mg/kg three times daily as compared to 2 mg/kg twice daily dosing.</p><p>&nbsp;</p><p><em>Study performed in neonates with persistent pulmonary hypertension of the newborn (PPHN):</em></p><p>&nbsp;</p><p>FUTURE 4 (AC-052-391)</p><p>This was a double-blind, placebo-controlled, randomised study in pre-term or term neonates (gestational age 36&ndash;42 weeks) with PPHN. Patients with suboptimal response to inhaled nitric oxide (iNO) despite at least 4 hours of continuous treatment were treated with bosentan dispersible tablets at 2 mg/kg twice daily (N = 13) or placebo (N = 8) via nasogastric tube as add-on therapy on top of iNO until complete weaning of iNO or until treatment failure (defined as need for extra-corporeal membrane oxygenation [ECMO] or initiation of alternative pulmonary vasodilator), and for a maximum of 14 days.</p><p>&nbsp;</p><p>The median exposure to study treatment was 4.5 (range: 0.5&ndash;10.0) days in the bosentan group and 4.0 (range: 2.5&ndash;6.5) days in the placebo group.</p><p>&nbsp;</p><p>The results did not indicate an additional benefit of bosentan in this population:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The median time to complete weaning from iNO was 3.7 days (95% confidence limits [CLs] 1.17, 6.95) on bosentan and 2.9 days (95% CLs 1.26, 4.23) on placebo (p = 0.34).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The median time to complete weaning from mechanical ventilation was 10.8 days (95% CLs 3.21, 12.21 days) on bosentan and 8.6 days (95% CLs 3.71, 9.66 days) on placebo (p = 0.24).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; One patient in the bosentan group had treatment failure (need for ECMO as per protocol definition), which was declared based on increasing Oxygenation Index values within 8 h after the first study drug dose. This patient recovered within the 60-day follow-up period.</p><p>&nbsp;</p><p><em>Combination with epoprostenol</em></p><p>The combination of bosentan and epoprostenol has been investigated in two studies: AC-052-355 (BREATHE-2) and AC-052-356 (BREATHE-3). AC-052-355 was a multi-centre, randomised, double‑blind, parallel-group study of bosentan versus placebo in 33 patients with severe PAH who were receiving concomitant epoprostenol therapy. AC‑052‑356 was an open-label, uncontrolled study; 10 of the 19 paediatric patients were on concomitant bosentan and epoprostenol therapy during the 12-week study. The safety profile of the combination was not different from the one expected with each component and the combination therapy was well tolerated in children and adults. The clinical benefit of the combination has not been demonstrated.</p><p>&nbsp;</p><p><em>Systemic</em><em> sclerosis with digital ulcer disease</em></p><p>Two randomised, double-blind, multi-centre, placebo-controlled studies have been conducted in 122 (study AC-052-401 [RAPIDS-1]) and 190 (study AC-052-331 [RAPIDS-2]) adult patients with systemic sclerosis and digital ulcer disease (either ongoing digital ulcers or a history of digital ulcers within the previous year). In study AC-052-331, patients had to have at least one digital ulcer of recent onset, and across the two studies 85% of patients had ongoing digital ulcer disease at baseline. After 4&nbsp;weeks of bosentan 62.5&nbsp;mg twice daily, the maintenance dose studied in both these studies was 125&nbsp;mg twice daily. The duration of double-blind therapy was 16 weeks in study AC-052-401, and 24&nbsp;weeks in study AC‑052‑331.</p><p>&nbsp;</p><p>Background treatments for systemic sclerosis and digital ulcers were permitted if they remained constant for at least 1&nbsp;month prior to the start of treatment and during the double-blind study period.</p><p>&nbsp;</p><p>The number of new digital ulcers from baseline to study endpoint was a primary endpoint in both studies. Treatment with bosentan resulted in fewer new digital ulcers for the duration of therapy, compared with placebo. In study AC-052-401, during 16 weeks of double-blind therapy, patients in the bosentan group developed a mean of 1.4 new digital ulcers vs 2.7 new digital ulcers in the placebo group (p&nbsp;=&nbsp;0.0042). In study AC-052-331, during 24 weeks of double-blind therapy, the corresponding figures were 1.9 vs 2.7 new digital ulcers, respectively (p = 0.0351). In both studies, patients on bosentan were less likely to develop multiple new digital ulcers during the study and took longer to develop each successive new digital ulcer than did those on placebo. The effect of bosentan on reduction of the number of new digital ulcers was more pronounced in patients with multiple digital ulcers.</p><p>&nbsp;</p><p>No effect of bosentan on time to healing of digital ulcers<strong> </strong>was observed in either study.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The pharmacokinetics of bosentan have mainly been documented in healthy subjects. Limited data in patients show that the exposure to bosentan in adult PAH patients is approximately 2-fold greater than in healthy adult subjects.</p><p>&nbsp;</p><p>In healthy subjects, bosentan displays dose- and time-dependent pharmacokinetics. Clearance and volume of distribution decrease with increased intravenous doses and increase with time. After oral administration, the systemic exposure is proportional to dose up to 500&nbsp;mg. At higher oral doses, C<sub>max</sub> and AUC increase less than proportionally to the dose.</p><p>&nbsp;</p><p><u>Absorption</u></p><p><em><u>&nbsp;</u></em></p><p>In healthy subjects, the absolute bioavailability of bosentan is approximately 50% and is not affected by food. The maximum plasma concentrations are attained within 3&ndash;5 hours.</p><p>&nbsp;</p><p><u>Distribution</u></p><p><em><u>&nbsp;</u></em></p><p>Bosentan is highly bound (&gt;&nbsp;98%) to plasma proteins, mainly albumin. Bosentan does not penetrate into erythrocytes.</p><p>&nbsp;</p><p>A volume of distribution (V<sub>ss</sub>) of about 18&nbsp;litres was determined after an intravenous dose of 250&nbsp;mg.</p><p>&nbsp;</p><p><u>Biotransformation and elimination</u></p><p>&nbsp;</p><p>After a single intravenous dose of 250&nbsp;mg, the clearance was 8.2&nbsp;L/h. The terminal elimination half-life (t<sub>1/2</sub>) is 5.4&nbsp;hours.</p><p>&nbsp;</p><p>Upon multiple dosing, plasma concentrations of bosentan decrease gradually to 50&ndash;65% of those seen after single dose administration. This decrease is probably due to auto-induction of metabolising liver enzymes. Steady-state conditions are reached within 3&ndash;5&nbsp;days.</p><p>&nbsp;</p><p>Bosentan is eliminated by biliary excretion following metabolism in the liver by the cytochrome P450 isoenzymes, CYP2C9 and CYP3A4. Less than 3% of an administered oral dose is recovered in urine.</p><p>&nbsp;</p><p>Bosentan forms three metabolites and only one of these is pharmacologically active. This metabolite is mainly excreted unchanged via the bile. In adult patients, the exposure to the active metabolite is greater than in healthy subjects. In patients with evidence of the presence of cholestasis, the exposure to the active metabolite may be increased.</p><p>&nbsp;</p><p>Bosentan is an inducer of CYP2C9 and CYP3A4 and possibly also of CYP2C19 and the P‑glycoprotein. <em>In vitro</em>, bosentan inhibits the bile salt export pump in hepatocyte cultures.</p><p>&nbsp;</p><p><em>In vitro</em> data demonstrated that bosentan had no relevant inhibitory effect on the CYP isoenzymes tested (CYP1A2, 2A6, 2B6, 2C8, 2C9, 2D6, 2E1, 3A4). Consequently, bosentan is not expected to increase the plasma concentrations of medicinal products metabolised by these isoenzymes.</p><p><u>&nbsp;</u></p><p><u>Pharmacokinetics in special populations</u></p><p><em><u>&nbsp;</u></em></p><p>Based on the investigated range of each variable, it is not expected that the pharmacokinetics of bosentan will be influenced by gender, body weight, race, or age in the adult population to any relevant extent.</p><p>&nbsp;</p><p><em>Children</em></p><p>Pharmacokinetics were studied in paediatric patients in 4 clinical studies (BREATHE-3, FUTURE 1, FUTURE-3 and FUTURE-4; see section 5.1). Due to limited data in children below 2 years of age, pharmacokinetics remain not well characterised in this age category.</p><p><em>&nbsp;</em></p><p>Study AC-052-356 (BREATHE-3) evaluated the pharmacokinetics of single and multiple oral doses of the film-coated tablet formulation of bosentan in 19 children aged from 3 to 15 years with PAH who were dosed on the basis of body weight with 2 mg/kg twice daily. In this study, the exposure to bosentan decreased with time in a manner consistent with the known auto-induction properties of bosentan. The mean AUC (CV%) values of bosentan in paediatric patients treated with 31.25, 62.5 or 125 mg twice daily were 3,496 (49), 5,428 (79), and 6,124 (27) ng&middot;h/mL, respectively, and were lower than the value of 8,149 (47) ng&middot;h/mL observed in adult patients with PAH receiving 125 mg twice daily. At steady state, the systemic exposures in paediatric patients weighing 10&ndash;20 kg, 20&ndash;40 kg and &gt; 40 kg were 43%, 67% and 75%, respectively, of the adult systemic exposure.</p><p>&nbsp;</p><p>In study AC-052-365 (FUTURE 1), dispersible tablets were administered in 36 PAH children aged from 2 to 11 years. No dose proportionality was observed, as steady-state bosentan plasma concentrations and AUCs were similar at oral doses of 2 and 4 mg/kg (AUC<sub>t</sub>: 3,577&nbsp;ng&middot;h/mL and 3,371 ng&middot;h/mL for 2&nbsp;mg/kg&nbsp;twice daily and 4&nbsp;mg/kg&nbsp;twice daily, respectively). The average exposure to bosentan in these paediatric patients was about half the exposure in adult patients at the 125 mg twice daily maintenance dose but showed a large overlap with the exposures in adults.</p><p>&nbsp;</p><p>In study AC-052-373 (FUTURE 3), using dispersible tablets, the exposure to bosentan in the patients treated with 2&nbsp;mg/kg twice daily was comparable to that in the FUTURE 1 study. In the overall population (n = 31), 2&nbsp;mg/kg twice daily resulted in a daily exposure of 8,535 ng&middot;h/mL; AUC<sub>t </sub>was 4,268&nbsp;ng&middot;h/mL (CV: 61%). In patients between 3 months and 2 years the daily exposure was 7,879 ng&middot;h/mL; AUC<sub>t</sub><sub> </sub>was 3,939&nbsp;ng&middot;h/mL (CV: 72%). In patients between 3 months and 1 year (n&nbsp;=&nbsp;2) AUC<sub>t</sub><sub> </sub>was 5,914&nbsp;ng&middot;h/mL (CV: 85%), and in patients between 1 and 2 years (n&nbsp;=&nbsp;7) AUC<sub>t</sub><sub> </sub>was 3,507&nbsp;ng&middot;h/mL (CV: 70%). In the patients above 2 years (n = 22) the daily exposure was 8,820 ng&middot;h/mL; AUC<sub>t</sub><sub>&nbsp;</sub>was 4,410&nbsp;ng&middot;h/mL (CV: 58%). Dosing bosentan 2 mg/kg three times daily did not increase exposure; daily exposure was 7,275 ng&middot;h/mL (CV: 83%, n = 27).</p><p>&nbsp;</p><p>Based on the findings in studies BREATHE-3, FUTURE 1, and FUTURE-3, it appears that the exposure to bosentan reaches a plateau at lower doses in paediatric patients than in adults, and that doses higher than 2 mg/kg twice daily (4 mg/kg twice daily or 2 mg/kg three times daily) will not result in greater exposure to bosentan in paediatric patients.</p><p>&nbsp;</p><p>In study AC-052-391 (FUTURE 4) conducted in neonates, bosentan concentrations increased slowly and continuously over the first dosing interval, resulting in low exposure (AUC<sub>0-12</sub> in whole blood: 164&nbsp;ng&middot;h/mL, n = 11). At steady state, AUC<sub>t</sub> was 6,165&nbsp;ng&middot;h/mL (CV: 133%, n = 7), which is similar to the exposure observed in adult PAH patients receiving 125 mg twice daily and taking into account a blood/plasma distribution ratio of 0.6.</p><p>&nbsp;</p><p>The consequences of these findings regarding hepatotoxicity are unknown.<strong> </strong>Gender and concomitant use of intravenous epoprostenol had no significant effect on the pharmacokinetics of bosentan.</p><p>&nbsp;</p><p><em>Hepatic impairment</em></p><p>In patients with mildly impaired liver function (Child-Pugh class A) no relevant changes in the pharmacokinetics have been observed. The steady-state AUC of bosentan was 9% higher and the AUC of the active metabolite, Ro&nbsp;48-5033, was 33% higher in patients with mild hepatic impairment than in healthy volunteers.</p><p>&nbsp;</p><p>The impact of moderately impaired liver function (Child-Pugh class B) on the pharmacokinetics of bosentan and its primary metabolite Ro&nbsp;48-5033 was investigated in a study including 5 patients with pulmonary hypertension associated with portal hypertension and Child-Pugh class B hepatic impairment, and 3 patients with PAH from other causes and normal liver function. In the patients with Child-Pugh class B liver impairment, the mean (95% CI) steady-state AUC of bosentan was 360 (212&ndash;613) ng&times;h/mL, i.e., 4.7 times higher, and the mean (95% CI) AUC of the active metabolite Ro 48-5033 was 106 (58.4&ndash;192) ng&times;h/mL, i.e., 12.4 times higher than in the patients with normal liver function (bosentan: mean [95% CI] AUC: 76.1 [9.07&ndash;638] ng&times;h/mL; Ro&nbsp;48‑5033: mean [95% CI] AUC 8.57 [1.28&ndash;57.2] ng&times;h/ml). Though the number of patients included was limited and with high variability, these data indicate a marked increase in the exposure to bosentan and its primary metabolite Ro&nbsp;48-5033 in patients with moderate liver function impairment (Child-Pugh class B).</p><p>&nbsp;</p><p>The pharmacokinetics of bosentan have not been studied in patients with Child-Pugh class C hepatic impairment. Tracleer is contraindicated in patients with moderate to severe hepatic impairment, i.e., Child-Pugh class B or C (see section 4.3).</p><p>&nbsp;</p><p><em>Renal impairment</em></p><p>In patients with severe renal impairment (creatinine clearance 15&ndash;30&nbsp;mL/min), plasma concentrations of bosentan decreased by approximately 10%. Plasma concentrations of bosentan metabolites increased about 2-fold in these patients as compared with subjects with normal renal function. No dose adjustment is required in patients with renal impairment. There is no specific clinical experience in patients undergoing dialysis. Based on physicochemical properties and the high degree of protein binding, bosentan is not expected to be removed from the circulation by dialysis to any significant extent (see section&nbsp;4.2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>A 2-year carcinogenicity study in mice showed an increased combined incidence of hepatocellular adenomas and carcinomas in males, but not in females, at plasma concentrations about 2 to 4&nbsp;times the plasma concentrations achieved at the therapeutic dose in humans. In rats, oral administration of bosentan for 2&nbsp;years produced a small, significant increase in the combined incidence of thyroid follicular cell adenomas and carcinomas in males, but not in females, at plasma concentrations about 9 to 14&nbsp;times the plasma concentrations achieved at the therapeutic dose in humans. Bosentan was negative in tests for genotoxicity.<em> </em>There was evidence of a mild thyroid hormonal imbalance induced by bosentan in rats. However, there was no evidence of bosentan affecting thyroid function (thyroxine, TSH) in humans.</p><p>&nbsp;</p><p>The effect of bosentan on mitochondrial function is unknown.</p><p>&nbsp;</p><p>Bosentan has been shown to be teratogenic in rats at plasma levels higher than 1.5&nbsp;times the plasma concentrations achieved at the therapeutic dose in humans. Teratogenic effects, including malformations of the head and face and of the major vessels, were dose dependent. The similarities of the pattern of malformations observed with other ET receptor antagonists and in ET knock-out mice indicate a class effect. Appropriate precautions must be taken for women of childbearing potential (see sections 4.3, 4.4 and 4.6).</p><p>&nbsp;</p><p>Development of testicular tubular atrophy and impaired fertility has been linked with chronic administration of endothelin receptor antagonists in rodents.</p><p>&nbsp;</p><p>In fertility studies in male and female rats, no effects on sperm count, motility and viability, or on mating performance or fertility were observed at exposures that were 21 and 43 times the expected therapeutic level in humans, respectively; nor was there any adverse effect on the development of the pre-implantation embryo or on implantation.</p><p>&nbsp;</p><p>Slightly increased incidence of testicular tubular atrophy was observed in rats given bosentan orally at doses as low as 125 mg/kg/day (about 4 times the maximum recommended human dose [MRHD] and the lowest doses tested) for two years but not at doses as high as 1,500 mg/kg/day (about 50 times the MRHD) for 6 months. In a juvenile rat toxicity study, where rats were treated from Day 4 <em>post partum</em> up to adulthood, decreased absolute weights of testes and epididymides, and reduced number of sperm in epididymides were observed after weaning. The NOAEL was 21 times (at Day 21 <em>post partum</em>) and 2.3 times (Day 69 <em>post partum</em>) the human therapeutic exposure, respectively.</p><p>&nbsp;</p><p>However, no effects on general development, growth, sensory, cognitive function and reproductive performance were detected at 7 (males) and 19 (females) times the human therapeutic exposure at Day 21 <em>post partum. </em>At adult age (Day 69 <em>post partum</em>), no effects of bosentan were detected at 1.3 (males) and 2.6 (females) times the therapeutic exposure in children with PAH.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core:</u></p><p>Maize starch</p><p>Pregelatinised starch</p><p>Sodium starch glycolate (Type A)</p><p>Povidone</p><p>Glycerol dibehenate</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Film coat:</u></p><p>Hypromellose</p><p>Glycerol triacetate</p><p>Talc</p><p>Titanium dioxide (E171)</p><p>Iron oxide yellow (E172)</p><p>Iron oxide red (E172)</p><p>Ethylcellulose</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years

For white high-density polyethylene bottles, use within 30 days after the first opening.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>For white high-density polyethylene bottles:</p><p>Do not store above 30 &deg;C.</p><p>For storage conditions after first opening of the medicinal product, see section 6.3.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tracleer 62.5&nbsp;mg film-coated tablets</u></p><p>White high-density polyethylene bottles with a silica gel desiccant containing 56 film-coated tablets.</p><p>Cartons contain 56 film-coated tablets.</p><p>&nbsp;</p><p><u>Tracleer 125&nbsp;mg film-coated tablets</u></p><p>White high-density polyethylene bottles with a silica gel desiccant containing 56 film-coated tablets.</p><p>Cartons contain 56 film-coated tablets.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements for disposal.</p><p>&nbsp;</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Actelion Pharmaceuticals Ltd
Gewerbestrasse 16
4123 Allschwil
Switzerland 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                05 September 2019 
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>